<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Anti‐vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion - Braithwaite, T - 2014 | Cochrane Library</title> <meta content="Anti‐vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion - Braithwaite, T - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007325.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Anti‐vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion - Braithwaite, T - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007325.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007325.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Anti‐vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion" name="citation_title"/> <meta content="Tasanee Braithwaite" name="citation_author"/> <meta content="Moorfields Eye Hospital NHS Foundation Trust" name="citation_author_institution"/> <meta content="tasaneebraithwaite@gmail.com" name="citation_author_email"/> <meta content="Afshan A Nanji" name="citation_author"/> <meta content="Bascom Palmer Eye Institute" name="citation_author_institution"/> <meta content="Kristina Lindsley" name="citation_author"/> <meta content="Johns Hopkins Bloomberg School of Public Health" name="citation_author_institution"/> <meta content="Paul B Greenberg" name="citation_author"/> <meta content="Warren Alpert Medical School of Brown University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD007325.pub3" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/05/01" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007325.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007325.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007325.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antibodies, Monoclonal, Humanized [therapeutic use]; Aptamers, Nucleotide [therapeutic use]; Bevacizumab; Macular Edema [*drug therapy, etiology]; Randomized Controlled Trials as Topic; Ranibizumab; Receptors, Vascular Endothelial Growth Factor [therapeutic use]; Recombinant Fusion Proteins [therapeutic use]; Retinal Vein Occlusion [*complications]; Vascular Endothelial Growth Factor A [*antagonists &amp; inhibitors]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007325.pub3&amp;doi=10.1002/14651858.CD007325.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007325.pub3&amp;doi=10.1002/14651858.CD007325.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007325.pub3&amp;doi=10.1002/14651858.CD007325.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007325.pub3&amp;doi=10.1002/14651858.CD007325.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007325.pub3&amp;doi=10.1002/14651858.CD007325.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007325.pub3&amp;doi=10.1002/14651858.CD007325.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007325.pub3&amp;doi=10.1002/14651858.CD007325.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007325.pub3&amp;doi=10.1002/14651858.CD007325.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007325.pub3&amp;doi=10.1002/14651858.CD007325.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007325.pub3&amp;doi=10.1002/14651858.CD007325.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007325.pub3&amp;doi=10.1002/14651858.CD007325.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007325.pub3&amp;doi=10.1002/14651858.CD007325.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007325.pub3&amp;doi=10.1002/14651858.CD007325.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007325.pub3&amp;doi=10.1002/14651858.CD007325.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007325.pub3&amp;doi=10.1002/14651858.CD007325.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007325.pub3&amp;doi=10.1002/14651858.CD007325.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007325.pub3&amp;doi=10.1002/14651858.CD007325.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007325.pub3&amp;doi=10.1002/14651858.CD007325.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007325.pub3&amp;doi=10.1002/14651858.CD007325.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007325.pub3&amp;doi=10.1002/14651858.CD007325.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007325.pub3&amp;doi=10.1002/14651858.CD007325.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007325.pub3&amp;doi=10.1002/14651858.CD007325.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007325.pub3&amp;doi=10.1002/14651858.CD007325.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="jiwTpTuf";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007325\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007325\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007325\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007325\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007325.pub3",title:"Anti\\u2010vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion",firstPublishedDate:"May 1, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Eyes and Vision Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jiwTpTuf&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007325.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007325.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007325.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007325.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007325.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007325.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007325.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007325.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007325.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007325.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2096 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007325.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007325.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007325.pub3/full#CD007325-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007325.pub3/full#CD007325-sec-0099"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007325.pub3/full#CD007325-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007325.pub3/full#CD007325-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007325.pub3/full#CD007325-sec-0038"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007325.pub3/full#CD007325-sec-0039"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007325.pub3/full#CD007325-sec-0066"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007325.pub3/full#CD007325-sec-0094"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007325.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007325.pub3/appendices#CD007325-sec-0104"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007325.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007325.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/table_n/CD007325StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/table_n/CD007325StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007325.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007325.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007325.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007325.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007325.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007325.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Anti‐vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007325.pub3/information#CD007325-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Tasanee Braithwaite</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007325.pub3/information#CD007325-cr-0003">Afshan A Nanji</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007325.pub3/information#CD007325-cr-0004">Kristina Lindsley</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007325.pub3/information#CD007325-cr-0005">Paul B Greenberg</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/information/en#CD007325-sec-0115">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 01 May 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007325.pub3">https://doi.org/10.1002/14651858.CD007325.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007325-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007325-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007325-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007325-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007325-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD007325-abs-0002">繁體中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007325-abs-0001" lang="en"> <section id="CD007325-sec-0001"> <h3 class="title" id="CD007325-sec-0001">Background</h3> <p>Central retinal vein occlusion (CRVO) is a relatively common retinal vascular disorder in which macular oedema may develop, with a consequent reduction in visual acuity. Until recently there has been no treatment of proven benefit, but growing evidence supports the use of anti‐vascular endothelial growth factor (anti‐VEGF) agents. </p> </section> <section id="CD007325-sec-0002"> <h3 class="title" id="CD007325-sec-0002">Objectives</h3> <p>To investigate the effectiveness and safety of anti‐VEGF therapies for the treatment of macular oedema secondary to CRVO. </p> </section> <section id="CD007325-sec-0003"> <h3 class="title" id="CD007325-sec-0003">Search methods</h3> <p>We searched CENTRAL (which contains the Cochrane Central Register of Controlled Trials (CENTRAL) and the Cochrane Eyes and Vision Group Trials Register) (<i>The Cochrane Library</i> 2013, Issue 10), Ovid MEDLINE (January 1950 to October 2013), EMBASE (January 1980 to October 2013), Latin American and Caribbean Health Sciences Literature Database (LILACS) (January 1982 to October 2013), Cumulative Index to Nursing and Allied Health Literature (CINAHL) (January 1937 to October 2013), OpenGrey, OpenSIGLE (January 1950 to October 2013), the <i>meta</i> Register of Controlled Trials (<i>m</i>RCT) (<a href="http://www.controlled-trials.com" target="_blank">www.controlled‐trials.com</a>), ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>), the WHO International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en) and Web of Science Conference Proceedings Citation Index‐Science (CPCI‐S). There were no language or date restrictions in the electronic search for trials. The electronic databases and clinical trials registers were last searched on 29th October 2013. </p> </section> <section id="CD007325-sec-0004"> <h3 class="title" id="CD007325-sec-0004">Selection criteria</h3> <p>We considered randomised controlled trials (RCTs) that compared intravitreal anti‐VEGF agents of any dose or duration to sham injection or no treatment. We focused on studies that included individuals of any age or gender and a minimum of six months follow‐up. </p> </section> <section id="CD007325-sec-0005"> <h3 class="title" id="CD007325-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed trial quality and extracted data. The primary outcome was the proportion of participants with a gain in best‐corrected visual acuity (BCVA) from baseline of greater than or equal to 15 letters (3 lines) on the Early Treatment of Diabetic Retinopathy Study (ETDRS) chart. Secondary outcomes included the proportion of participants with a loss of 15 letters or more of BCVA, the mean change from baseline BCVA, the mean change in central retinal thickness (CRT), the number and type of complications or adverse outcomes, and the number of additional interventions administered. Where available, we also presented quality of life and economic data. </p> </section> <section id="CD007325-sec-0006"> <h3 class="title" id="CD007325-sec-0006">Main results</h3> <p>We found six RCTs that met the inclusion criteria after independent and duplicate review of the search results. These RCTs included 937 participants and compared outcomes at six months to sham injection for four anti‐VEGF agents: aflibercept (VEGF Trap‐Eye, Eylea), bevacizumab (Avastin), pegaptanib sodium (Macugen) and ranibizumab (Lucentis). Three trials were conducted in Norway, Sweden and the USA, and three trials were multicentre, one including centres in the USA, Canada, India, Israel, Argentina and Columbia, a second including centres in the USA, Australia, France, Germany, Israel, and Spain, and a third including centres in Austria, France, Germany, Hungary, Italy, Latvia, Australia, Japan, Singapore and South Korea. We performed meta‐analysis on three key visual outcomes, using data from up to six trials. High‐quality evidence from six trials revealed that participants receiving intravitreal anti‐VEGF treatment were 2.71 times more likely to gain at least 15 letters of visual acuity at six months compared to participants treated with sham injections (risk ratio (RR) 2.71; 95% confidence intervals (CI) 2.10 to 3.49). High‐quality evidence from five trials suggested anti‐VEGF treatment was associated with an 80% lower risk of losing at least 15 letters of visual acuity at six months compared to sham injection (RR 0.20; 95% CI 0.12 to 0.34). Moderate‐quality evidence from three trials (481 participants) revealed that the mean reduction from baseline to six months in central retinal thickness was 267.4 µm (95% CI 211.4 µm to 323.4 µm) greater in participants treated with anti‐VEGF than in participants treated with sham. The meta‐analyses demonstrate that treatment with anti‐VEGF is associated with a clinically meaningful gain in vision at six months. One trial demonstrated sustained benefit at 12 months compared to sham. No significant ocular or systemic safety concerns were identified in this time period. </p> </section> <section id="CD007325-sec-0007"> <h3 class="title" id="CD007325-sec-0007">Authors' conclusions</h3> <p>Compared to no treatment, repeated intravitreal injection of anti‐VEGF agents in eyes with CRVO macular oedema improved visual outcomes at six months. All agents were relatively well tolerated with a low incidence of adverse effects in the short term. Future trials should address the relative efficacy and safety of the anti‐VEGF agents and other treatments, including intravitreal corticosteroids, for longer‐term outcomes. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007325-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007325-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007325-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007325-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007325-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD007325-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007325-abs-0005" lang="en"> <h3>Anti‐vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion </h3> <p><b>Review question</b> <br/> We reviewed the evidence about the effect of anti‐vascular endothelial growth factor (anti‐VEGF) agents in people with macular oedema secondary to central retinal vein occlusion (CRVO). </p> <p><b>Background</b> <br/> CRVO affects approximately one person per 1000 at any one time, and is associated with increasing age, high blood pressure, diabetes, glaucoma and various disorders of the blood. It frequently causes sudden, painless vision loss in one eye, although sometimes the vision loss may be minimal. If the vein blockage leads to inadequate oxygen delivery to the sensitive retinal tissue, the CRVO is the 'non‐perfused' or 'ischaemic' subtype. More commonly, blood flow and oxygen delivery are restored following the vein blockage and the CRVO is the 'perfused' or 'non‐ischaemic' subtype, and has a better visual outcome. Various other complications may develop over hours, days, weeks or months. These include macular oedema, in which fluid collects within the retina and causes reduction in vision. Until relatively recently there has been no evidence‐based treatment for this condition. Anti‐VEGF agents have been used successfully to treat patients with other retinal vascular disorders, including several conditions associated with macular oedema. </p> <p><b>Study characteristics</b> <br/> This systematic review identified six trials which included 937 participants with macular oedema secondary to CRVO (as of 29 October 2013). The trials compared sham injections with one of four types of anti‐VEGF agents: aflibercept (VEGF Trap‐Eye, Eylea), bevacizumab (Avastin), pegaptanib sodium (Macugen) and ranibizumab (Lucentis). All trials treated participants for at least six months. Three trials were multicentre, international trials and three were conducted in Norway, Sweden or the USA. </p> <p><b>Key results</b> <br/> Overall, treatment with anti‐VEGF agents increased the chance of a significant gain in vision (at least 3 lines on the vision chart) at six months by more than two and a half times, compared to no treatment. Furthermore, the risk of losing significant vision (at least 3 lines on the vision chart) was reduced by 80% in those receiving anti‐VEGF therapy compared to those receiving no treatment. No significant safety concerns were identified at six or 12 months, but the available studies do not allow a conclusion about their long‐term effectiveness and safety to be drawn. Nevertheless, the availability of anti‐VEGF treatment for CRVO macular oedema represents an important advance in the clinical management options for this sight‐threatening disease. </p> <p><b>Quality of the evidence</b> <br/> The six trials included in this review were high quality and consistently demonstrated visual benefit from anti‐VEGF injections. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007325-sec-0099" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007325-sec-0099"></div> <h3 class="title" id="CD007325-sec-0100">Implications for practice</h3> <section id="CD007325-sec-0100"> <p>The randomised controlled trial (RCT) evidence from six trials clearly demonstrates that repeated intravitreal injection therapy for central retinal vein occlusion (CRVO) macular oedema with the anti‐vascular endothelial growth factor (anti‐VEGF) agents ranibizumab, pegaptanib sodium, aflibercept and bevacizumab, improves visual and anatomical outcomes at six and 12 months, compared to sham treatment. Smaller subgroup analyses suggest that early initiation of treatment (within two months or 90 days of diagnosis) is probably more beneficial than delayed treatment. Clinical benefit has been demonstrated by a few trials in subgroups of patients with both ischaemic and non‐ischaemic CRVO macular oedema at baseline, and with baseline best‐corrected visual acuity (BCVA) both better than and worse than 6/60. The efficacy and safety of anti‐VEGF therapy, and of repeat intravitreal injections, over longer periods of follow‐up has yet to be determined. </p> <p>The relative effectiveness and safety profile of anti‐VEGF agents versus steroid therapies for the treatment of different subgroups of CRVO macular oedema was not explored in this review and has yet to be determined. The impact of prior or combined treatment with intravitreal corticosteroid, or other treatments, was also not explored in this review. </p> <p>In summary, anti‐VEGF therapy is a relatively safe and effective treatment for CRVO macular oedema in the short term, and this represents an important therapeutic advance for the treatment of this visually disabling disease. It is not yet possible to determine the potential economic impact of the use of anti‐VEGF agents in this clinical context, but we will be reassess this if data become available. </p> </section> <h3 class="title" id="CD007325-sec-0101">Implications for research</h3> <section id="CD007325-sec-0101"> <p>That anti‐VEGF therapy confers clear clinical benefit for the treatment of CRVO macular oedema over no treatment (sham) in patients with certain baseline characteristics has been demonstrated, and marketing licenses have been granted to several agents accordingly. Future research should explore the relative efficacy and safety of different anti‐VEGF agents in head‐to‐head trials, and other treatments (including corticosteroid injections and implants) and combination therapies. Further research into the efficacy and safety of anti‐VEGF treatment for patients excluded from the trials reviewed here is needed. In particular, there is a clinical need to determine whether anti‐VEGF therapy is also beneficial to patients with a duration from diagnosis exceeding a year, to those with ocular comorbidity and to those with a baseline visual acuity of 6/12 or better. Trials including larger patient samples would be needed to ensure sufficient statistical power for important subgroup analyses to be performed. Longer‐term outcomes data on anti‐VEGF treatment groups would also be valuable, to investigate whether the apparently low incidence of ocular and systemic adverse events is maintained in the longer term, or if there are any ocular or systemic harms associated with chronic VEGF inhibition. </p> <p>The burden placed on patients and healthcare systems of monthly reassessment and repeat injection is very considerable, and the relative efficacy of different treatment intervals and approaches to reassessment and retreatment needs to be investigated further. The length of treatment to achieve a stable visual outcome has also yet to be determined. Recent trials have demonstrated that patients with both ischaemic and non‐ischaemic CRVO macular oedema, with baseline BCVA worse than and better than 6/60, and with shorter and longer duration of disease at baseline all benefit, to a greater or lesser extent, from anti‐VEGF therapy. Comprehensive baseline assessment to permit stratification and subgroup analysis would facilitate exploration of the prognostic significance of these important baseline factors. The inclusion of patients with a baseline BCVA better than 6/12 in future trials would also provide valuable clinical management information for this important subset of patients to whom the existing trial data do not necessarily apply. Further epidemiological data from different populations on the risk factors for developing CRVO macular oedema would also be beneficial. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007325-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007325-sec-0029"></div> <div class="table" id="CD007325-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Anti‐VEGF compared with sham injection for CRVO macular oedema</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with CRVO macular oedema of duration less than 9 months (mean &lt; 3 months) and no prior treatment </p> <p><b>Settings:</b> presenting baseline visual acuity ranging from 6 (&lt; 6/120) letters to 73 letters (˜6/12), both non‐ischaemic and ischaemic eyes (% ischaemic at baseline of included trials ranged from 0% to 16%) </p> <p><b>Intervention:</b> intravitreal injection with ranibizumab, bevacizumab, aflibercept or pegaptanib sodium </p> <p><b>Comparison:</b> sham injection </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Sham injection</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Anti‐VEGF injection</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BCVA gain of 15 letters or more</p> <p>(follow‐up: 6 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>182 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>493 per 1000</b> <br/> (382 to 635) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.71</b> (2.10 to 3.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>937<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Includes all 4 anti‐VEGF agents</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BCVA loss of 15 letters or more</p> <p>(follow‐up: 6 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>219 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 1000</b> <br/> (26 to 74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.20</b> (0.12 to 0.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>766<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Includes all 4 anti‐VEGF agents</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change in BCVA from baseline</p> <p>(follow‐up: 6 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change across control groups ranged from loss of 4 letters to gain of 3 letters</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean gain across treatment groups ranged from +7.1 letters to + 18.0 letters</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 15.23 letters</b> (11.57 to 18.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>937<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard deviation or 95% CI not reported in 2 studies (aflibercept and pegaptanib sodium) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change from baseline in central retinal thickness</p> <p>(follow‐up: 6 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction from baseline in CRT across control groups ranged from<br/> ‐102 to ‐169 microns (6 studies, 937 participants) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction from baseline in CRT in the intervention groups was ‐267 microns greater (‐211 to ‐323 microns) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD ‐267.4 µm</b> (211.4 to 323.4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>481<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard deviation or 95% CI not reported in 3 studies (aflibercept and pegaptanib sodium) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Complication: iris or retinal neovascularisation</p> <p>(follow‐up: 6 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>75 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000</p> <p>(7 to 27)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.18</b> (0.09 to 0.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>936</p> <p>(6 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Includes all 4 anti‐VEGF agents</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ocular adverse events: endophthalmitis at 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No cases in 347 participants treated with sham injection</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 case in 590 participants treated with intravitreal injection of anti‐VEGF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>937</p> <p>(6 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Includes all 4 anti‐VEGF agents</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change from baseline in quality of life score (NEI VFQ‐25 instrument)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean gain in quality of life score from baseline across control groups ranged from +0.8 to +3.5 points </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean gain in quality of life score from baseline across control groups ranged from +6.2 to +7.5 points </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>743</p> <p>(3 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard deviation or 95% CI not reported in 2 studies (aflibercept)<br/> &gt; 4‐point increase is considered a clinically relevant improvement </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Anti‐VEGF:</b> anti‐vascular endothelial growth factor; <b>BCVA:</b> best‐corrected visual acuity; <b>CI:</b> confidence interval;<b>CRT:</b> central retinal thickness; <b>CRVO:</b> central retinal vein occlusion; <b>MD:</b> mean difference; <b>NEI‐VFQ 25:</b> National Eye Institute Visual Functioning Questionnaire 25 question instrument; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>*Assumed risk was taken from the mean baseline risk from studies in the meta‐analysis and was equal to the total number of events in the control groups divided by the total number of participants in the control groups. </p> <p>Judgement of high quality: most evidence comes from RCTs at low risk of bias, with no unexplained heterogeneity and consistent results, low probability of publication bias, a large magnitude of effect or an apparent dose‐response gradient. </p> <p>Judgement of moderate quality: most of the evidence comes from RCTs with some limitations. For example, limitations include an unclear risk of bias in one or several domains or few participants and wide confidence intervals suggesting imprecision of evidence. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007325-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007325-sec-0030"></div> <section id="CD007325-sec-0031"> <h3 class="title" id="CD007325-sec-0031">Description of the condition</h3> <p>Central retinal vein occlusion (CRVO) is a common retinal vascular disorder in which macular oedema, including the cystoid type, may develop with a consequent reduction in visual acuity (<a href="./references#CD007325-bbs2-0046" title="Guex‐CrosierY . The pathogenesis and clinical presentation of macular edema in inflammatory diseases. Documenta Ophthalmologica1999;97(3‐4):297‐309. ">Guex‐Crosier 1999</a>; <a href="./references#CD007325-bbs2-0048" title="HayrehSS . Classification of central retinal vein occlusion. Ophthalmology1983;90(5):458‐74. ">Hayreh 1983</a>). Cystoid macular oedema is characterised by the collection of fluid in intercellular spaces within the outer plexiform layer of the retina and results from the breakdown of the capillary endothelium blood‐retinal barrier and leakage of fluid from the vasculature (<a href="./references#CD007325-bbs2-0046" title="Guex‐CrosierY . The pathogenesis and clinical presentation of macular edema in inflammatory diseases. Documenta Ophthalmologica1999;97(3‐4):297‐309. ">Guex‐Crosier 1999</a>; <a href="./references#CD007325-bbs2-0084" title="VinoresSA , DerevjanikNL , OzakiH , OkamotoN , CampochiaroPA . Cellular mechanisms of blood‐retinal barrier dysfunction in macular edema. Documenta Ophthalmologica1999;97(3‐4):217‐28. ">Vinores 1999</a>). This process is promoted by vascular endothelial growth factor (VEGF) (<a href="./references#CD007325-bbs2-0084" title="VinoresSA , DerevjanikNL , OzakiH , OkamotoN , CampochiaroPA . Cellular mechanisms of blood‐retinal barrier dysfunction in macular edema. Documenta Ophthalmologica1999;97(3‐4):217‐28. ">Vinores 1999</a>), and the aqueous concentration of VEGF has been found to be significantly elevated in patients with CRVO macular oedema compared to controls (<a href="./references#CD007325-bbs2-0037" title="FunkM , KriechbaumK , PragerF , BeneschT , GeorgopoulosM , ZlabingerGJ , et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Investigative Ophthalmology &amp; Visual Science2009;50(3):1025‐32. ">Funk 2009</a>). Furthermore, there is a significant inverse association between duration since onset of CRVO macular oedema and the aqueous VEGF concentration (<a href="./references#CD007325-bbs2-0037" title="FunkM , KriechbaumK , PragerF , BeneschT , GeorgopoulosM , ZlabingerGJ , et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Investigative Ophthalmology &amp; Visual Science2009;50(3):1025‐32. ">Funk 2009</a>). Macular oedema can be visualised with slit‐lamp biomicroscopy and its thickness and pattern of distribution can be investigated and quantified using optical coherence tomography (OCT) (<a href="./references#CD007325-bbs2-0024" title="CatierA , TadayoniR , PaquesM , ErginayA , HaouchineB , GaudricA , et al. Characterization of macular edema from various etiologies by optical coherence tomography. American Journal of Ophthalmology2005;140(2):200‐6. ">Catier 2005</a>; <a href="./references#CD007325-bbs2-0054" title="HeeMR , PuliafitoCA , WongC , DukerJS , ReichelE , RutledgeB , et al. Quantitative assessment of macular edema with optical coherence tomography. Archives of Ophthalmology1995;113(8):1019‐29. ">Hee 1995</a>). </p> <p>Central retinal vein occlusion is classified into two subtypes, 'non‐ischaemic' (also called 'perfused') and 'ischaemic' (also called 'non‐perfused'), although it is unlikely that the disease process is binary. No single test reliably differentiates the two subtypes with 100% sensitivity and specificity during the early acute phase of CRVO (<a href="./references#CD007325-bbs2-0049" title="HayrehSS , KlugmanMR , BeriM , KimuraAE , PodhajskyP . Differentiation of ischemic from non‐ischemic central retinal vein occlusion during the early acute phase. Graefes Archive for Clinical and Experimental Ophthalmology1990;228(3):201‐17. ">Hayreh 1990a</a>). Fundus fluorescein angiography (FFA) is frequently used to define ischaemic CRVO (<a href="./references#CD007325-bbs2-0026" title="ClarksonJG . Central Vein Occlusion Study: photographic protocol and early natural history. Transactions of the American Ophthalmological Society1994;92:203‐13; discussion 213‐5. ">Clarkson 1994</a>; <a href="./references#CD007325-bbs2-0028" title="CVOS Group. Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group. Archives of Ophthalmology1997;115(10):1275. ">CVOS Group 1997</a>). However, standard FFA may be reliable in fewer than 60% of cases (<a href="./references#CD007325-bbs2-0049" title="HayrehSS , KlugmanMR , BeriM , KimuraAE , PodhajskyP . Differentiation of ischemic from non‐ischemic central retinal vein occlusion during the early acute phase. Graefes Archive for Clinical and Experimental Ophthalmology1990;228(3):201‐17. ">Hayreh 1990a</a>), on account of masking from extensive retinal haemorrhages, which frequently persist in the first six months, poor images resulting from media opacities (vitreous haemorrhage or lens opacities, which are frequent in the affected age group), and inadequate assessment of the peripheral retina (<a href="./references#CD007325-bbs2-0049" title="HayrehSS , KlugmanMR , BeriM , KimuraAE , PodhajskyP . Differentiation of ischemic from non‐ischemic central retinal vein occlusion during the early acute phase. Graefes Archive for Clinical and Experimental Ophthalmology1990;228(3):201‐17. ">Hayreh 1990a</a>). However, ultra wide‐field FFA is increasingly used in clinical practice to provide up to 200º imaging of the retina using a non‐contact lens‐based system (<a href="./references#CD007325-bbs2-0072" title="PrasadPS , OliverSC , CoffeeRE , HubschmanJP , SchwartzSD . Ultra wide‐field angiographic characteristics of branch retinal and hemicentral retinal vein occlusion. Ophthalmology2010;117(4):780‐4. ">Prasad 2010</a>). </p> <section id="CD007325-sec-0032"> <h4 class="title">Epidemiology</h4> <p>The burden of CRVO macular oedema in the population and the incidence of macular oedema following CRVO are unknown (<a href="./references#CD007325-bbs2-0062" title="McIntoshRL , RogersSL , LimL , CheungN , WangJJ , MitchellP , et al. Natural history of central retinal vein occlusion: an evidence‐based systematic review. Ophthalmology2010;117(6):1113‐23. ">McIntosh 2010</a>), and there is still a paucity of data on risk factors for developing macular oedema following CRVO (<a href="./references#CD007325-bbs2-0051" title="HayrehSS , ZimmermanMB , PodhajskyP . Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. American Journal of Ophthalmology1994;117(4):429‐41. ">Hayreh 1994</a>). </p> <p>The age‐ and sex‐standardised prevalence of CRVO has been estimated at 0.80 per 1000 persons (95% confidence interval (CI) 0.61 to 0.99), giving an estimated global burden (for the 2008 population) of 2.5 million affected adults (<a href="./references#CD007325-bbs2-0076" title="RogersS , McIntoshRL , CheungN , LimL , WangJJ , MitchellP , et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology2010;117(2):313‐9. ">Rogers 2010</a>). In this pooled analysis, including 11 population‐based studies on 49,869 participants in the United States, Asia, Europe and Australia, the prevalence of CRVO was found to increase with age, with a crude prevalence ranging from 0.27 per 1000 (95% CI 0 to 0.65) in those aged 40 to 49 years, to 5.44 per 1000 (95% CI 2.78 to 8.10) in those aged 80 years and over (<a href="./references#CD007325-bbs2-0076" title="RogersS , McIntoshRL , CheungN , LimL , WangJJ , MitchellP , et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology2010;117(2):313‐9. ">Rogers 2010</a>). Of these participants, 43.7% were male, 48.4% were white, 27.1% were Asian, 17.2% were Hispanic and 7.2% were black, and the prevalence did not differ by race or by gender. In another study of 1302 people diagnosed with CRVO in the USA, black people had a 58% increased risk of CRVO compared to white people (hazard ratio (HR) 1.58; 95% CI 1.25 to 1.99) and women had a 25% decreased risk compared to men (HR 0.75; 95% CI 0.66 to 0.85), after adjustment for known confounders (<a href="./references#CD007325-bbs2-0080" title="StemMS , TalwarN , ComerGM , SteinJD . A longitudinal analysis of risk factors associated with central retinal vein occlusion. Ophthalmology2013;120(2):362‐70. ">Stem 2013</a>). Numerous other factors increase the hazard of CRVO, including a hypercoagulable state (HR 2.92; 95% CI 1.52 to 2.42), a diagnosis of stroke (HR 1.44; 95% CI 1.23 to 1.68), end‐organ damage from hypertension (HR 1.92; 95% CI 1.52 to 2.42) and end‐organ damage from diabetes mellitus (HR 1.53; 95% CI 1.28 to 1.84), relative to people without these conditions (<a href="./references#CD007325-bbs2-0080" title="StemMS , TalwarN , ComerGM , SteinJD . A longitudinal analysis of risk factors associated with central retinal vein occlusion. Ophthalmology2013;120(2):362‐70. ">Stem 2013</a>). After developing a CRVO there is a 1% chance per year of a retinal vein occlusion in the fellow eye (<a href="./references#CD007325-bbs2-0028" title="CVOS Group. Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group. Archives of Ophthalmology1997;115(10):1275. ">CVOS Group 1997</a>). CRVO is associated with an increase in mortality on account of its statistical association with comorbid diabetes or cardiovascular disease (<a href="./references#CD007325-bbs2-0020" title="BertelsenM , LinnebergA , ChristoffersenN , VorumH , GadeE , LarsenM . Mortality in patients with central retinal vein occlusion. Ophthalmology2014;121(3):637‐42. ">Bertelsen 2013</a>). </p> </section> <section id="CD007325-sec-0033"> <h4 class="title">Natural history and prognosis</h4> <p>There is a paucity of population‐level data on the prevalence and incidence of ischaemic versus non‐ischaemic CRVO macular oedema, but the distinction is important because their presentation and natural history differ (<a href="./references#CD007325-bbs2-0053" title="HayrehSS , PodhajskyPA , ZimmermanMB . Natural history of visual outcome in central retinal vein occlusion. Ophthalmology2011;118(1):119‐33. ">Hayreh 2011</a>). The ischaemic subtype of CRVO accounts for approximately 20% of acute presentations (<a href="./references#CD007325-bbs2-0048" title="HayrehSS . Classification of central retinal vein occlusion. Ophthalmology1983;90(5):458‐74. ">Hayreh 1983</a>; <a href="./references#CD007325-bbs2-0051" title="HayrehSS , ZimmermanMB , PodhajskyP . Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. American Journal of Ophthalmology1994;117(4):429‐41. ">Hayreh 1994</a>) and is associated with worse baseline acuity and a poor visual prognosis, even after the resolution of macular oedema (<a href="./references#CD007325-bbs2-0028" title="CVOS Group. Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group. Archives of Ophthalmology1997;115(10):1275. ">CVOS Group 1997</a>; <a href="./references#CD007325-bbs2-0053" title="HayrehSS , PodhajskyPA , ZimmermanMB . Natural history of visual outcome in central retinal vein occlusion. Ophthalmology2011;118(1):119‐33. ">Hayreh 2011</a>). In a natural history cohort study (n = 697 eyes with CRVO), baseline visual acuity was 6/30 (20/100) or better in 78% of patients with non‐ischaemic CRVO and in only 1% with ischaemic CRVO, and visual field defects were mild in 91% and 8%, respectively (<a href="./references#CD007325-bbs2-0053" title="HayrehSS , PodhajskyPA , ZimmermanMB . Natural history of visual outcome in central retinal vein occlusion. Ophthalmology2011;118(1):119‐33. ">Hayreh 2011</a>). Final visual acuity, after resolution of macular oedema, was 6/30 (20/100) or better in 83% with non‐ischaemic CRVO and 12% with ischaemic CRVO (<a href="./references#CD007325-bbs2-0053" title="HayrehSS , PodhajskyPA , ZimmermanMB . Natural history of visual outcome in central retinal vein occlusion. Ophthalmology2011;118(1):119‐33. ">Hayreh 2011</a>). In non‐ischaemic CRVO, development of foveal pigmentary degeneration, epiretinal membrane or both has been identified as the main cause of poor final acuity (<a href="./references#CD007325-bbs2-0053" title="HayrehSS , PodhajskyPA , ZimmermanMB . Natural history of visual outcome in central retinal vein occlusion. Ophthalmology2011;118(1):119‐33. ">Hayreh 2011</a>). Visual morbidity, including blindness, may also result from persistent macular oedema, ocular neovascularisation or secondary glaucoma (<a href="./references#CD007325-bbs2-0008" title="CampochiaroPA , HafizG , ShahSM , NguyenQD , YingH , DoDV , et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Molecular Therapy2008;16(4):791‐9. CampochiaroPA , ShahSM , HafizG , QuinlanE , Zimmer‐GllerI , NguyenQD , et al. Ranibizumab for macular edema due to retinal vein occlusions. Investigative Ophthalmology and Visual Science2007; Vol. 48. ARVO E‐abstract 1545. ">Campochiaro 2008</a>). The risk of developing these complications also differs between the subtypes, with 16.6% of eyes with more than 5.5 disc areas of non‐perfusion on FFA at baseline, versus 4.0% of eyes with less than 5.5 disc areas of non‐perfusion, developing neovascular glaucoma at 36 months (<a href="./references#CD007325-bbs2-0025" title="ChanCK , IpMS , VanveldhuisenPC , OdenNL , ScottIU , TolentinoMJ , et al. SCORE Study report #11: incidences of neovascular events in eyes with retinal vein occlusion. Ophthalmology2011;118(7):1364‐72. ">Chan 2011</a>). The non‐ischaemic type may convert to the ischaemic type in an estimated one‐third of cases within three years, and conversion is most frequent in the initial four months (<a href="./references#CD007325-bbs2-0028" title="CVOS Group. Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group. Archives of Ophthalmology1997;115(10):1275. ">CVOS Group 1997</a>). </p> <p>Presenting visual acuity is also a key predictor of visual outcome at three years, considering ischaemic and non‐ischaemic subtypes together (<a href="./references#CD007325-bbs2-0028" title="CVOS Group. Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group. Archives of Ophthalmology1997;115(10):1275. ">CVOS Group 1997</a>). Out of 714 eyes with CRVO, 65% of patients with presenting visual acuity better than or equal to 6/12 (20/40) were found to maintain this level of vision; those with presenting visual acuity 6/12 to 6/60 (20/40 to 20/200) have a variable prognosis with 19% improving to better than 6/15 (20/50), 44% showing no improvement and 37% worsening to less than 6/60 (20/200); whilst 80% of those with vision less than 6/60 (20/200) at presentation have no visual improvement. In another natural history study, amongst non‐ischaemic eyes (n = 588) with an initial visual acuity of approximately 6/24 (20/70) or worse, 59% improved, 27% showed no change and 14% deteriorated on resolution of macular oedema, whereas amongst those with ischaemic CRVO (n = 109), 41% improved, 41% did not change and 18% deteriorated (<a href="./references#CD007325-bbs2-0053" title="HayrehSS , PodhajskyPA , ZimmermanMB . Natural history of visual outcome in central retinal vein occlusion. Ophthalmology2011;118(1):119‐33. ">Hayreh 2011</a>). An intact external limiting membrane in the outer retina at baseline, which can be visualised with spectral‐domain OCT, has also been found to predict better visual outcomes after treatment (<a href="./references#CD007325-bbs2-0086" title="Wolf‐SchnurrbuschUE , GhanemR , RothenbuehlerSP , EnzmannV , FrammeC , WolfS . Predictors of short‐term visual outcome after anti‐VEGF therapy of macular edema due to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2011;52(6):3334‐7. ">Wolf‐Schnurrbusch 2011</a>). </p> </section> <section id="CD007325-sec-0034"> <h4 class="title">History of the management of CRVO macular oedema</h4> <p>Historically, there was no evidence‐based treatment for CRVO macular oedema. Various medical and surgical interventions had been tried, including argon laser panretinal photocoagulation (<a href="./references#CD007325-bbs2-0050" title="HayrehSS , KlugmanMR , PodhajskyP , ServaisGE , PerkinsES . Argon laser panretinal photocoagulation in ischemic central retinal vein occlusion. A 10‐year prospective study. Graefes Archive for Clinical and Experimental Ophthalmology1990;228(4):281‐96. ">Hayreh 1990b</a>), macular grid photocoagulation (<a href="./references#CD007325-bbs2-0027" title="CVOS Group. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology1995;102(10):1425‐33. ">CVOS Group 1995</a>), tissue plasminogen activator (<a href="./references#CD007325-bbs2-0033" title="EverettAI , YangSS . Venous occlusive disease: the latest in current management. Retina2006;26(6):S63‐4. ">Everett 2006</a>), oral pentoxifylline (<a href="./references#CD007325-bbs2-0068" title="ParkCH , ScottAW , FekratS . Effect of oral pentoxifylline on cystoid macular edema associated with central retinal vein occlusion. Retina2007;27(8):1020‐5. ">Park 2007</a>), hyperbaric oxygen therapy (<a href="./references#CD007325-bbs2-0087" title="WrightJK , FranklinB , ZantE . Clinical case report: treatment of a central retinal vein occlusion with hyperbaric oxygen. Undersea &amp; Hyperbaric Medicine2007;34(5):315‐9. ">Wright 2007</a>) and pars plana vitrectomy with internal limiting membrane peeling (<a href="./references#CD007325-bbs2-0029" title="DeCroosFC , ShulerRKJr , StinnettS , FekratS . Pars plana vitrectomy, internal limiting membrane peeling, and panretinal endophotocoagulation for macular edema secondary to central retinal vein occlusion. American Journal of Ophthalmology2009;147(4):627‐33. ">DeCroos 2009</a>; <a href="./references#CD007325-bbs2-0069" title="ParkDH , KimIT . Long‐term effects of vitrectomy and internal limiting membrane peeling for macular edema secondary to central retinal vein occlusion and hemiretinal vein occlusion. Retina2010;30(1):117‐24. ">Park 2010</a>; <a href="./references#CD007325-bbs2-0074" title="Raszewska‐SteglinskaM , GozdekP , CisieckiS , MichalewskaZ , MichalewskiJ , NawrockiJ . Pars plana vitrectomy with ILM peeling for macular edema secondary to retinal vein occlusion. European Journal of Ophthalmology2009;19(6):1055‐62. ">Raszewska‐Steglinska 2009</a>), but these were not effective. Evidence for the effect of optic neurotomy has been mixed (<a href="./references#CD007325-bbs2-0016" title="ArevaloJF , GarciaRA , WuL , RodriguezFJ , Dalma‐WeiszhauszJ , Quiroz‐MercadoH , et al. Radial optic neurotomy for central retinal vein occlusion: results of the Pan‐American Collaborative Retina Study Group (PACORES). Retina2008;28(8):1044‐52. ">Arevalo 2008</a>; <a href="./references#CD007325-bbs2-0047" title="HasselbachHC , RueferF , FeltgenN , SchneiderU , BoppS , HansenLL , et al. Treatment of central retinal vein occlusion by radial optic neurotomy in 107 cases. Graefes Archive for Clinical and Experimental Ophthalmology2007;245(8):1145‐56. ">Hasselbach 2007</a>; <a href="./references#CD007325-bbs2-0065" title="OpremcakEM , RehmarAJ , RidenourCD , KurzDE . Radial optic neurotomy for central retinal vein occlusion: 117 consecutive cases. Retina2006;26(3):297‐305. ">Opremcak 2006</a>; <a href="./references#CD007325-bbs2-0090" title="ZambarakjiHJ , Ghazi‐NouriS , SchadtM , BunceC , HykinPG , CharterisDG . Vitrectomy and radial optic neurotomy for central retinal vein occlusion: effects on visual acuity and macular anatomy. Graefes Archive for Clinical and Experimental Ophthalmology2005;243(5):397‐405. ">Zambarakji 2005</a>), with one recent randomised controlled trial (RCT) suggesting possible benefit (<a href="./references#CD007325-bbs2-0014" title="AggermannT , BrunnerS , KrebsI , HaasP , WomastekI , BrannathW , et al. ROVO Study Group. A prospective, randomised, multicenter trial for surgical treatment of central retinal vein occlusion: results of the Radial Optic Neurotomy for Central Vein Occlusion (ROVO) study group. Graefes Archive for Clinical and Experimental Ophthalmology2013;251(4):1065‐72. ">Aggermann 2012</a>). A RCT comparing laser‐induced chorioretinal venous anastomosis to sham treatment in adults with non‐ischaemic CRVO macular oedema of three to 12 months' duration demonstrated moderate efficacy, especially in the 76% who developed a functioning anastomosis following laser treatment, and the visual acuity advantage compared to control was maintained at 18 months (<a href="./references#CD007325-bbs2-0061" title="McAllisterIL , GilliesME , SmithiesLA , RochtchinaE , HarperCA , DaniellMD , et al. The Central Retinal Vein Bypass Study: a trial of laser‐induced chorioretinal venous anastomosis for central retinal vein occlusion. Ophthalmology2010;117(5):954‐65. ">McAllister 2010</a>). However, 18% in the treatment arm developed neovascularisation at the treatment site and 9% required vitrectomy surgery for macular traction or non‐resolving vitreous haemorrhage (<a href="./references#CD007325-bbs2-0061" title="McAllisterIL , GilliesME , SmithiesLA , RochtchinaE , HarperCA , DaniellMD , et al. The Central Retinal Vein Bypass Study: a trial of laser‐induced chorioretinal venous anastomosis for central retinal vein occlusion. Ophthalmology2010;117(5):954‐65. ">McAllister 2010</a>). </p> <p>More significantly, two RCTs on corticosteroids for CRVO macular oedema demonstrated short‐term effectiveness, but concerns have been raised about the incidence of complications (<a href="./references#CD007325-bbs2-0042" title="GewailyD , GreenbergP B . Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD007324.pub2] ">Gewaily 2009</a>). Firstly, the 'Standard Care vs. Corticosteroid for Retinal Vein Occlusion' trial treated participants with non‐ischaemic CRVO macular oedema with either 1 mg or 4 mg intravitreal triamcinolone (IVTA) injections repeated every four months, or observation alone (<a href="./references#CD007325-bbs2-0077" title="IpMS , ScottIU , VanVeldhuisenPC , OdenNL , BlodiBA , FisherM , et al. SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: The standard care vs corticosteroid for retinal vein occlusion (SCORE) study report 5. Archives of Ophthalmology2009;127(9):1101‐14. ">SCORE 2009</a>). Both treatment doses were associated with a five times increase in the odds of achieving a 15 letter gain in visual acuity at 12 months (P = 0.001). However, 35% of patients treated with 4 mg, and 20% of patients treated with 1 mg, required intraocular pressure lowering treatment by 12 months compared to 8% in the observation group (<a href="./references#CD007325-bbs2-0077" title="IpMS , ScottIU , VanVeldhuisenPC , OdenNL , BlodiBA , FisherM , et al. SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: The standard care vs corticosteroid for retinal vein occlusion (SCORE) study report 5. Archives of Ophthalmology2009;127(9):1101‐14. ">SCORE 2009</a>). Similarly, at 12 months there was new lens opacity, or progression of existing lens opacity, in 33% of the 4 mg group and 26% of the 1 mg group, compared to 18% of the observation group (<a href="./references#CD007325-bbs2-0077" title="IpMS , ScottIU , VanVeldhuisenPC , OdenNL , BlodiBA , FisherM , et al. SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: The standard care vs corticosteroid for retinal vein occlusion (SCORE) study report 5. Archives of Ophthalmology2009;127(9):1101‐14. ">SCORE 2009</a>). Secondly, the Ozurdex GENEVA trial compared a single dexamethasone implant (Ozurdex, Allergan, Inc., Irvine, CA) at a dose of 0.7 mg or 0.35 mg, to a sham implant, in adults with non‐ischaemic branch retinal vein occlusion (BRVO) or CRVO macular oedema of six weeks to nine months duration, and baseline acuity of 6/15 (68 letters, 20/50) to 6/60 (34 letters, 20/20) (<a href="./references#CD007325-bbs2-0066" title="HallerJA , BandelloF , BelfortR , BlumenkranzMS , GilliesM , HeierJ , et al. The OZURDEX GENEVA Study Group. Randomized, sham‐controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology2010;117(6):1134‐46. ">Ozurdex GENEVA 2010</a>). The percentage of eyes with CRVO macular oedema achieving a 15 letter improvement in visual acuity was significantly higher in both Ozurdex groups at day 30 and day 60 than in the sham group (P &lt; 0.001), with the maximal effect at day 60. However, by days 90 and 180 there was no significant difference between groups (<a href="./references#CD007325-bbs2-0066" title="HallerJA , BandelloF , BelfortR , BlumenkranzMS , GilliesM , HeierJ , et al. The OZURDEX GENEVA Study Group. Randomized, sham‐controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology2010;117(6):1134‐46. ">Ozurdex GENEVA 2010</a>). The incidence of ocular adverse events was not reported for CRVO macular oedema separately, but did not differ significantly between the 0.35 mg and 0.7 mg dose groups. In both groups there was a higher incidence of ocular hypertension at day 60 (P &lt; 0.002), and by day 180 approximately 24% of patients with dexamethasone implants required intraocular pressure (IOP)‐lowering medication, and five patients required a surgical or laser procedure to reduce IOP (<a href="./references#CD007325-bbs2-0066" title="HallerJA , BandelloF , BelfortR , BlumenkranzMS , GilliesM , HeierJ , et al. The OZURDEX GENEVA Study Group. Randomized, sham‐controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology2010;117(6):1134‐46. ">Ozurdex GENEVA 2010</a>). There was also a significant increase in anterior chamber activity in the 0.35 mg (P = 0.007) and 0.7 mg (P = 0.03) treatment groups compared to sham (P = 0.03), but no significant increase in the risk of incident cataract at 180 days (<a href="./references#CD007325-bbs2-0066" title="HallerJA , BandelloF , BelfortR , BlumenkranzMS , GilliesM , HeierJ , et al. The OZURDEX GENEVA Study Group. Randomized, sham‐controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology2010;117(6):1134‐46. ">Ozurdex GENEVA 2010</a>). In a subsequent six‐month, open‐label extension, all patients were eligible for a single 0.7 mg Ozurdex implant, regardless of initial treatment assignment, if BCVA was &lt; 84 letters (6/6, 20/20) or CRT was &gt; 250 μm (<a href="./references#CD007325-bbs2-0067" title="HallerJA , BandelloF , BelfortRJr , BlumenkranzMS , GilliesM , HeierJ , et al. The OZURDEX GENEVA Study Group. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve‐month study results. Ophthalmology2011;118(12):2453‐60. ">Ozurdex GENEVA 2011</a>). Amongst patients who received two treatments with 0.7 mg implants for CRVO, six months apart (n = 114), mean BCVA improvements were similar after the first and second injections, with a peak improvement of approximately 8 to 10 letters at 60 days. Patients randomised to receive sham injection in the first six months who subsequently received 0.7 mg dexamethasone (n = 117) had an average gain of approximately 6 to 7 letters at 60 days. There was no apparent sustained visual acuity gain at 12 months in either group. Summed safety data for CRVO and BRVO patients who received a 0.7 mg implant at day 180 (n = 997) were reported. Over 12 months, cataract progression occurred in 29.8% of phakic eyes that received two 0.7 mg implants, versus 5.7% of sham‐treated phakic eyes. In the former treatment group (n = 341), a &gt; 10 mmHg IOP rise was observed in 12.6% after the first treatment and 15.4% after the second treatment, and in the majority this was transient or controlled with topical medication. However, a laser or surgical procedure to reduce IOP was required for 14 treated eyes compared to no eyes in the untreated group (<a href="./references#CD007325-bbs2-0067" title="HallerJA , BandelloF , BelfortRJr , BlumenkranzMS , GilliesM , HeierJ , et al. The OZURDEX GENEVA Study Group. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve‐month study results. Ophthalmology2011;118(12):2453‐60. ">Ozurdex GENEVA 2011</a>). There are currently no RCTs exploring the efficacy or safety of more frequent treatment with dexamethasone implants, or with follow‐up beyond 12 months. Despite this, the UK National Institute of Clinical Excellence (NICE) have recently approved Ozurdex implants as a treatment option for CRVO macular oedema, with a suggested repeat interval of six months, to a total of six implants per patient. </p> </section> </section> <section id="CD007325-sec-0035"> <h3 class="title" id="CD007325-sec-0035">Description of the intervention</h3> <p>Monoclonal antibodies against VEGF were first developed as an intravenous treatment for metastatic colorectal cancer (<a href="./references#CD007325-bbs2-0057" title="HomsiJ , DaudAI . Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control2007;14(3):285‐94. ">Homsi 2007</a>; <a href="./references#CD007325-bbs2-0059" title="LosM , RoodhartJM , VoestEE . Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist2007;12(4):443‐50. ">Los 2007</a>). The first drug licensed for this purpose was bevacizumab (Avastin®), which received Food and Drug Administration (FDA) approval in 2004 (<a href="./references#CD007325-bbs2-0041" title="Genentech/Roche . Avastin: Product Information Home. www.gene.com/gene/products/information/oncology/avastin/2009. ">Genentech/Roche 2009b</a>). Bevacizumab is a 149kDa recombinant humanised monoclonal whole immunoglobulin G1 antibody that binds to VEGF and blocks the binding of VEGF to receptors (Flt‐1 and KDR) on endothelial cells (<a href="./references#CD007325-bbs2-0039" title="Genentech , Inc . Avastin: Full prescribing information. www.gene.com/gene/products/information/pdf/avastin‐prescribing.pdf2009. ">Genentech 2009</a>). It is not licensed for intraocular use, although there has been widespread off‐licence intravitreal use in the USA and Europe. Pegaptanib sodium (Macugen®) is a 50kDa aptamer; a pegylated modified oligonucleotide, which adopts a three‐dimensional configuration in vivo that allows it to bind to extracellular VEGF‐165 and antagonise its biological effects (<a href="./references#CD007325-bbs2-0034" title="Eyetech , Inc . Macugen ‐ Pegatanib sodium injection. www.macugen.com/macugenUSPI.pdf2008. ">Eyetech 2008</a>; <a href="./references#CD007325-bbs2-0044" title="GragoudasES , AdamisAP , CunninghamET , Feinsod JrM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. ">Gragoudas 2004</a>). It was approved by the FDA in 2004, and the European Medicines Agency in 2006, for use in neovascular age‐related macular degeneration (wet AMD) (<a href="./references#CD007325-bbs2-0034" title="Eyetech , Inc . Macugen ‐ Pegatanib sodium injection. www.macugen.com/macugenUSPI.pdf2008. ">Eyetech 2008</a>). Ranibizumab (Lucentis®) is a 48kDa recombinant humanised monoclonal immunoglobulin G1 antibody fragment (kappa isotype) that binds to the receptors of all biologically active isoforms of VEGF‐A and blocks the binding of VEGF‐A to VEGFR1 and VEGFR2 receptors on endothelial cells (<a href="./references#CD007325-bbs2-0038" title="Genentech , Inc . Lucentis: Full prescribing information. www.gene.com/gene/products/information/pdf/lucentis‐prescribing.pdf2008. ">Genentech 2008</a>). Ranibizumab has a binding affinity for VEGF approximately 100 times greater than bevacizumab (<a href="./references#CD007325-bbs2-0036" title="FerraraN , DamicoL , ShamsN , LowmanH , KimR . Development of ranibizumab, an anti‐vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age‐related macular degeneration. Retina (Philadelphia, Pa.)2006;26(8):859‐70. ">Ferrara 2006</a>). It was approved for the treatment of wet AMD by the FDA in 2006 and by NICE in 2008 (<a href="./references#CD007325-bbs2-0040" title="Genentech/Roche . Lucentis ‐ Ranibizumab injection: Product Information Home. www.gene.com/gene/products/information/tgr/lucentis/2009. ">Genentech/Roche 2009a</a>); for the treatment of retinal vein occlusion by the FDA in June 2010; and for the treatment of diabetic macular oedema by the FDA in August 2012, and by NICE in October 2012. Aflibercept (Eylea®, vascular endothelial growth factor Trap‐Eye; Regeneron Pharmaceuticals, Tarrytown, NY) is a 115kDa decoy receptor fusion protein comprising the second domain of human VEGF receptor 1 and the third domain of VEGF receptor 2 fused to the constant Fc domain of human immunoglobulin G1 (<a href="./references#CD007325-bbs2-0031" title="EconomidesAN , CarpenterLR , RudgeJS , WongV , Koehler‐StecEM , HartnettC , et al. Cytokine traps: multi‐component, high‐affinity blockers of cytokine action. Nature Medicine2003;9(1):47‐52. ">Economides 2003</a>). It has a greater binding affinity for VEGF than bevacizumab and ranibizumab (<a href="./references#CD007325-bbs2-0082" title="StewartMW , GripponS , KirkpatrickP . Aflibercept. Nature Reviews. Drug Discovery2012; Vol. 11, issue 4:269‐70. ">Stewart 2012</a>), and mathematical modelling indicates that it may require less frequent dosing than shorter‐acting anti‐VEGF agents (<a href="./references#CD007325-bbs2-0081" title="StewartMW , RosenfeldPJ . Predicted biological activity of intravitreal VEGF Trap. British Journal of Ophthalmology2008;92(5):667‐8. ">Stewart 2008</a>). It was approved by the FDA for the treatment of wet AMD in November 2011 and for CRVO macular oedema in September 2012. </p> <p>The pharmacokinetics of 1.25 mg bevacizumab and 0.5 mg ranibizumab intravitreal injections have been investigated in an experimental rabbit model (<a href="./references#CD007325-bbs2-0017" title="BakriSJ , SnyderMR , ReidJM , PulidoJS , EzzatMK , SinghRJ . Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology2007;114(12):2179‐82. ">Bakri 2007a</a>; <a href="./references#CD007325-bbs2-0018" title="BakriSJ , SnyderMR , ReidJM , PulidoJS , SinghRJ . Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology2007;114(5):855‐9. ">Bakri 2007b</a>). The vitreous concentration of both drugs declined in a monoexponential function, with a half‐life of 4.32 days for bevacizumab, and 2.88 days for ranibizumab. At 30 days both drugs persisted in the vitreous, at a concentration of &gt; 0.1 μg/ml for ranibizumab versus &gt; 10 μg/ml for bevacizumab. No ranibizumab was detected in the fellow eye or serum, whilst a peak serum concentration of bevacizumab of 3.3 μg/ml was reached at eight days, with a half‐life of 6.86 days, and very low concentrations (ng/ml) were detected in the fellow eye throughout the 29‐day study. The aqueous half‐life of a single 1.5 mg intravitreal injection of bevacizumab has also been studied in humans with various causes of macular oedema and has been found to be approximately 9.8 days (<a href="./references#CD007325-bbs2-0058" title="KrohneTU , EterN , HolzFG , MeyerCH . Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. American Journal of Ophthalmology2008;146(4):508‐12. ">Krohne 2008</a>). Patients with CRVO demonstrate moderate variability in the aqueous concentration of ranibizumab measured one month after a first intravitreal injection of 0.3 mg or 0.5 mg, but measurements one month following subsequent injections are highly correlated for a given patient (<a href="./references#CD007325-bbs2-0022" title="CampochiaroPA , ChoyDF , DoDV , GulnarH , ShahSM , NguyenQD , et al. Monitoring ocular drug therapy by analysis of aqueous samples. Ophthalmology2009;116(11):2158‐64. ">Campochiaro 2009</a>). </p> <p>The anti‐VEGF agents have demonstrated promise in treating CRVO macular oedema in many retrospective and prospective case series, and in a number of RCTs in recent years. </p> </section> <section id="CD007325-sec-0036"> <h3 class="title" id="CD007325-sec-0036">How the intervention might work</h3> <p>Vascular endothelial growth factor is a cytokine produced by cells in response to hypoxia that promotes vascular leakage by binding to receptors on endothelial cells. It has been observed that transgenic mice over‐expressing VEGF in the photoreceptors exhibited blood‐retina barrier failure (<a href="./references#CD007325-bbs2-0084" title="VinoresSA , DerevjanikNL , OzakiH , OkamotoN , CampochiaroPA . Cellular mechanisms of blood‐retinal barrier dysfunction in macular edema. Documenta Ophthalmologica1999;97(3‐4):217‐28. ">Vinores 1999</a>). Another study observed that injecting VEGF intravitreally induces a time and dose‐dependent breakdown of the blood‐aqueous and blood‐retinal barriers in a rabbit model, with maximal vascular leakage occurring 48 hours after injection (<a href="./references#CD007325-bbs2-0032" title="EdelmanJL , LutzD , CastroMR . Corticosteroids inhibit VEGF‐induced vascular leakage in a rabbit model of blood‐retinal and blood‐aqueous barrier breakdown. Experimental Eye Research2005;80(2):249‐58. ">Edelman 2005</a>). Animal and human studies have identified that the expression of VEGF mRNA is significantly upregulated in regions of ischaemic retina of various causes, including CRVO (<a href="./references#CD007325-bbs2-0070" title="Pe'erJ , ShweikiD , ItinA , HemoI , GnessinH , KeshetE . Hypoxia‐induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Laboratory Investigation1995;72(6):638‐45. ">Pe'er 1995</a>; <a href="./references#CD007325-bbs2-0071" title="Pe'erJ , FolbergR , ItinA , GnessinH , HemoI , KeshetE . Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology1998;105(3):412‐6. ">Pe'er 1998</a>; <a href="./references#CD007325-bbs2-0079" title="ShimaDT , GougosA , MillerJW , TolentinoM , RobinsonG , AdamisAP , et al. Cloning and mRNA expression of vascular endothelial growth factor in ischemic retinas of Macaca fascicularis. Investigative Ophthalmology &amp; Visual Science1996;37(7):1334‐40. ">Shima 1996</a>). Serum amyloid A, a major acute phase protein, and the cytokine IL‐6, which is derived from activated T lymphocytes and induces expression of VEGF and vascular permeability, have been found to be significantly elevated in the aqueous humour of eyes with CRVO macular oedema compared to control eyes (<a href="./references#CD007325-bbs2-0035" title="FengJ , ZhaoT , ZhangY , MaY , JiangY . Differences in aqueous concentrations of cytokines in macular edema secondary to branch and central retinal vein occlusion.. PLoS One2013;8(7):e68149. ">Feng 2013</a>). In a rat model of CRVO, injection of bevacizumab fully prevented the upregulation of VEGF‐A after one day and the upregulation of pigment‐epithelium‐derived factor after three days, which is known to influence the development of vascular oedema (<a href="./references#CD007325-bbs2-0030" title="DrechslerF , KoferlP , HollbornM , WiedemannP , BringmannA , KohenL , RehakM . Effect of intravitreal anti‐vascular endothelial growth factor treatment on the retinal gene expression in acute experimental central retinal vein occlusion. Ophthalmic Research2012;47(3):157‐62. ">Drechsler 2012</a>). Bevacizumab also decreased the upregulation of the proinflammatory cytokine interleukin (IL)‐1B which otherwise developed one day after a CRVO (<a href="./references#CD007325-bbs2-0030" title="DrechslerF , KoferlP , HollbornM , WiedemannP , BringmannA , KohenL , RehakM . Effect of intravitreal anti‐vascular endothelial growth factor treatment on the retinal gene expression in acute experimental central retinal vein occlusion. Ophthalmic Research2012;47(3):157‐62. ">Drechsler 2012</a>). Furthermore, the concentration of VEGF in human aqueous demonstrates close temporal correlation with the course of neovascularisation and permeability in CRVO, and injecting anti‐VEGF antibodies inhibits VEGF‐driven neovascularisation both in vitro and in vivo (<a href="./references#CD007325-bbs2-0013" title="AdamisAP , ShimaDT , TolentinoMJ , GragoudasES , FerraraN , FolkmanJ , et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia‐associated iris neovascularization in a nonhuman primate. Archives of Ophthalmology1996;114(1):66‐71. ">Adamis 1996</a>; <a href="./references#CD007325-bbs2-0015" title="AielloLP , PierceEA , FoleyED , TakagiH , ChenHRL , FerraraN , et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF‐receptor chimeric proteins. Proceedings of the National Academy of Sciences1995;92(23):10457‐61. ">Aiello 1995</a>; <a href="./references#CD007325-bbs2-0021" title="BoydSR , ZacharyI , ChakravarthyU , AllenGJ , WisdomGB , CreeIA , et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Archives of Ophthalmology2002;120(12):1644‐50. ">Boyd 2002</a>). Significant correlations have been identified between the aqueous VEGF concentration in patients with CRVO macular oedema and different components of the full‐field electroretinography (ERG) including the b/a ratio of the single flash ERG, implicit times of the cone a‐wave, cone b‐wave and 30 Hz flicker ERG leading to the suggestion that full‐field ERGs could be used to detect patients at high risk of developing neovascularisation (<a href="./references#CD007325-bbs2-0089" title="YasudaS , KachiS , KondoM , UshidaH , UetaniR , TeruiT , et al. Significant correlation between electroretinogram parameters and ocular vascular endothelial growth factor concentration in central retinal vein occlusion eyes. Investigative Ophthalmology and Visual Science2011;52(8):5737‐42. ">Yasuda 2011</a>). </p> <p>Whilst VEGF‐A has been identified as an important anti‐angiogenic target in retinal diseases, it has more recently also been recognised to play an important role in neuroprotection in the retina (<a href="./references#CD007325-bbs2-0064" title="NishijimaK , NgYS , ZhongL , BradleyJ , SchubertW , JoN , et al. Vascular endothelial growth factor‐A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. American Journal of Pathology2007;171(1):53‐67. ">Nishijima 2007</a>). In a model of ischaemia‐reperfusion injury VEGF‐A exposure resulted in a dose‐dependent reduction in retinal neuron apoptosis. Furthermore, ischaemic preconditioning, which increases VEGF‐A levels, was found to reduce the number of apoptotic retinal cells after injury, suggesting its role in the adaptive response to retinal ischaemia, and this protective effect was reversed with VEGF‐A inhibition (<a href="./references#CD007325-bbs2-0064" title="NishijimaK , NgYS , ZhongL , BradleyJ , SchubertW , JoN , et al. Vascular endothelial growth factor‐A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. American Journal of Pathology2007;171(1):53‐67. ">Nishijima 2007</a>). Chronic VEGF‐A inhibition in adult animals was also found to result in a significant loss of retinal ganglion cells, and the requirement for VEGF‐A in the maintenance of normal vasculature has now been recognised (<a href="./references#CD007325-bbs2-0064" title="NishijimaK , NgYS , ZhongL , BradleyJ , SchubertW , JoN , et al. Vascular endothelial growth factor‐A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. American Journal of Pathology2007;171(1):53‐67. ">Nishijima 2007</a>). Interestingly, pegaptanib sodium, which does not bind to VEGF‐120, did not reduce retinal ganglion cell viability in this animal model (<a href="./references#CD007325-bbs2-0064" title="NishijimaK , NgYS , ZhongL , BradleyJ , SchubertW , JoN , et al. Vascular endothelial growth factor‐A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. American Journal of Pathology2007;171(1):53‐67. ">Nishijima 2007</a>). In a small RCT of 19 participants with neovascular glaucoma secondary to ischaemic CRVO and poor baseline visual acuity, six months after randomisation to a single bevacizumab injection with panretinal photocoagulation (PRP) (n = 10) versus PRP alone (n = 9), neovascularisation had resolved in the bevacizumab group, but the a‐ and b‐wave amplitudes of the combined rod‐cone response and the b‐wave amplitudes of the 30 Hz flicker response were markedly reduced, suggesting a potential adverse effect of anti‐VEGF treatment on photoreceptor function (<a href="./references#CD007325-bbs2-0085" title="WittstromE , HolmbergH , HvarfnerC , AndreassonS . Clinical and electrophysiologic outcome in patients with neovascular glaucoma treated with and without bevacizumab. European Journal of Ophthalmology2012;22(4):563‐74. ">Wittstrom 2012</a>). These basic science and clinical studies illustrate that it should not be assumed that different anti‐VEGF agents will have the same biological and clinical effects, or that all effects of VEGF blockade are beneficial. </p> </section> <section id="CD007325-sec-0037"> <h3 class="title" id="CD007325-sec-0037">Why it is important to do this review</h3> <p>The visual prognosis in CRVO macular oedema is poor in a substantial proportion of patients, especially those with the ischaemic subtype, and until recently there was no treatment of proven benefit (<a href="./references#CD007325-bbs2-0033" title="EverettAI , YangSS . Venous occlusive disease: the latest in current management. Retina2006;26(6):S63‐4. ">Everett 2006</a>; <a href="./references#CD007325-bbs2-0052" title="HayrehSS . Management of central retinal vein occlusion. Ophthalmologica2003;217(3):167‐88. ">Hayreh 2003</a>; <a href="./references#CD007325-bbs2-0073" title="PriscoD , MarcucciR . Retinal vein thrombosis: risk factors, pathogenesis and therapeutic approach. Pathophysiology of Haemostasis &amp; Thrombosis2002;32(5‐6):308‐11. ">Prisco 2002</a>). Ranibizumab and aflibercept have now been approved in the US for the treatment of CRVO macular oedema, and clinicians internationally are increasingly using various anti‐VEGF agents both on‐ and off‐label for the treatment of CRVO macular oedema, based on emerging clinical experience and short‐term trial evidence. This systematic review was therefore designed to investigate the effectiveness and safety of anti‐VEGF agents for the treatment of CRVO macular oedema. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007325-sec-0038" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007325-sec-0038"></div> <p>To investigate the effectiveness and safety of anti‐VEGF therapies for the treatment of macular oedema secondary to CRVO. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007325-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007325-sec-0039"></div> <section id="CD007325-sec-0040"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007325-sec-0041"> <h4 class="title">Types of studies</h4> <p>We included RCTs with a minimum of six months follow‐up.</p> </section> <section id="CD007325-sec-0042"> <h4 class="title">Types of participants</h4> <p>We included trials involving participants of all ages who had unilateral or bilateral macular oedema secondary to CRVO. </p> </section> <section id="CD007325-sec-0043"> <h4 class="title">Types of interventions</h4> <p>We included trials in which anti‐VEGF treatment was compared to placebo or no treatment, and trials that investigated dosage and duration of treatment. We excluded studies in which anti‐VEGF agents were only compared to, or used in combination with, other agents. </p> </section> <section id="CD007325-sec-0044"> <h4 class="title">Types of outcome measures</h4> <section id="CD007325-sec-0045"> <h5 class="title">Primary outcomes</h5> <p>The primary outcome for this review was the proportion of participants with an improvement from baseline in best‐corrected visual acuity (BCVA) of greater than or equal to 15 letters (3 lines) on the Early Treatment in Diabetic Retinopathy Study (ETDRS) Chart at four metres, after six months of follow‐up, and any additional follow‐up times. A gain of 15 letters represents a doubling of the visual angle, and whilst this binary cut‐off considerably exceeds the amount of change required to have a high degree of certainty that the observed change is real, even in the presence of poor vision, it has been the standard primary outcome measure for evaluating the efficacy of treatments for retinal diseases for more than a decade (<a href="./references#CD007325-bbs2-0019" title="BeckRW , MaguireMG , BresslerNM , GlassmanAR , LindbladAS , FerrisFL . Visual acuity as an outcome measure in clinical trials of retinal disease. Ophthalmology2007;114(10):1804‐9. ">Beck 2007</a>). </p> </section> <section id="CD007325-sec-0046"> <h5 class="title">Secondary outcomes</h5> <p>We included the following secondary outcomes, at six months and any additional follow‐up times: </p> <p> <ol id="CD007325-list-0001"> <li> <p>The proportion of participants with a loss of 15 letters or more (ETDRS) compared to baseline. </p> </li> <li> <p>Mean visual acuity change.</p> </li> <li> <p>Objective assessment of macular oedema regression measured by mean change in central retinal thickness (CRT) on ocular coherence tomography (OCT). </p> </li> <li> <p>The number and type of complications relating to CRVO.</p> </li> <li> <p>The number of anti‐VEGF or sham injections administered.</p> </li> <li> <p>The number and type of additional interventions administered.</p> </li> </ol> </p> <section id="CD007325-sec-0047"> <h6 class="title">Adverse outcomes</h6> <p>We documented any ocular or systemic adverse outcomes reported in the trials, which were potentially related to the intervention or to intravitreal injection. We specifically aimed to report the proportion of participants experiencing potentially serious systemic or ocular adverse events including, but not limited to, retinal tears, retinal detachment, ocular inflammation, endophthalmitis, thromboembolic events, ocular hypertension, glaucoma (excluding neovascular) and cataract. </p> </section> <section id="CD007325-sec-0048"> <h6 class="title">Economic data</h6> <p>We reported any cost‐benefit data included in the primary studies.</p> </section> <section id="CD007325-sec-0049"> <h6 class="title">Quality of life data</h6> <p>We reported any data relating to impact on health‐ or vision‐related quality of life or daily functioning included in the primary studies. </p> </section> </section> </section> </section> <section id="CD007325-sec-0050"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD007325-sec-0051"> <h4 class="title">Electronic searches</h4> <p>We searched CENTRAL (which contains the Cochrane Central Register of Controlled Trials (CENTRAL) and the Cochrane Eyes and Vision Group Trials Register) (<i>The Cochrane Library</i> 2013, Issue 10), Ovid MEDLINE (January 1950 to October 2013), EMBASE (January 1980 to October 2013), Latin American and Caribbean Health Sciences Literature Database (LILACS) (January 1982 to October 2013), Cumulative Index to Nursing and Allied Health Literature (CINAHL) (January 1937 to October 2013), OpenGrey, OpenSIGLE (January 1950 to October 2013), the <i>meta</i> Register of Controlled Trials (<i>m</i>RCT) (<a href="http://www.controlled-trials.com" target="_blank">www.controlled‐trials.com</a>), ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>), the WHO International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en) and Web of Science Conference Proceedings Citation Index‐Science (CPCI‐S). There were no language or date restrictions in the electronic search for trials. The electronic databases and clinical trials registers were last searched on 29th October 2013. </p> <p>See: Appendices for details of search strategies for CENTRAL (<a href="./appendices#CD007325-sec-0105">Appendix 1</a>), MEDLINE (<a href="./appendices#CD007325-sec-0106">Appendix 2</a>), EMBASE (<a href="./appendices#CD007325-sec-0107">Appendix 3</a>), LILACS (<a href="./appendices#CD007325-sec-0108">Appendix 4</a>), CINAHL (<a href="./appendices#CD007325-sec-0109">Appendix 5</a>), OpenSIGLE, <i>m</i>RCT (<a href="./appendices#CD007325-sec-0110">Appendix 6</a>) and ClinicalTrials.gov (<a href="./appendices#CD007325-sec-0112">Appendix 8</a>). </p> </section> <section id="CD007325-sec-0052"> <h4 class="title">Searching other resources</h4> <p>We manually searched references of included studies and used the Science Citation Index to identify additional studies citing trials. </p> </section> </section> <section id="CD007325-sec-0053"> <h3 class="title" id="CD007325-sec-0053">Data collection and analysis</h3> <section id="CD007325-sec-0054"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently screened the titles and abstracts resulting from the electronic and manual searches. We classified abstracts as relevant, potentially relevant or not relevant for this review. We obtained full‐text copies of articles for those abstracts that were designated relevant or potentially relevant. Two review authors independently assessed each article and determined whether to definitely include, definitely exclude or record each trial as unclear. We documented agreement between review authors and resolved discrepancies by consensus. For any studies classified as unclear we contacted the authors in an attempt to include or exclude the study from the review. We reported any studies that were definitely excluded. </p> </section> <section id="CD007325-sec-0055"> <h4 class="title">Data extraction and management</h4> <p>We extracted the following participant and trial characteristics and reported them in a table format. </p> <p> <ol id="CD007325-list-0002"> <li> <p>Methodology (group size, randomisation and masking).</p> </li> <li> <p>Participant characteristics (gender, age, type of CRVO and diagnostic criteria used, baseline visual acuity, OCT‐determined thickness of macular oedema). </p> </li> <li> <p>Intervention (agent, dose, timing of first dose in relation to diagnosis, delivery route, frequency and treatment length). </p> </li> <li> <p>Primary and secondary outcomes (proportion with 15 letter gain in visual acuity at six months, proportion with 15 letter loss in visual acuity at six months, mean difference in visual acuity at six months compared to baseline, central retinal thickness, adverse events and outcomes at longer follow‐up intervals). </p> </li> <li> <p>Additional data (economic, quality of life and visual functioning data).</p> </li> <li> <p>Treatment compliance and losses to follow‐up.</p> </li> </ol> </p> <p>Two review authors independently extracted the data using a form developed by the Cochrane Eyes and Vision Group. We contacted trial authors for more information when data were missing or difficult to interpret. We resolved any discrepancies between the two review authors by discussion and consensus. One review author entered the data into Review Manager 5 (<a href="./references#CD007325-bbs2-0075" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011. ">RevMan 2011</a>) and the second author checked the entered data for any errors or inconsistencies. </p> </section> <section id="CD007325-sec-0056"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors assessed the methodological quality of the selected trials according to the methods set out in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007325-bbs2-0056" title="HigginsJPT , GreenS . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We considered the following domains: </p> <p> <ol id="CD007325-list-0003"> <li> <p>random sequence generation (selection bias);</p> </li> <li> <p>allocation concealment (selection bias);</p> </li> <li> <p>masking of participants and personnel (performance bias);</p> </li> <li> <p>masking of outcome assessment (detection bias);</p> </li> <li> <p>incomplete outcome data (attrition bias);</p> </li> <li> <p>selective reporting (reporting bias); and</p> </li> <li> <p>other sources of bias.</p> </li> </ol> </p> <p>We documented relevant information on each domain in a 'Risk of bias' table for each study. Each assessor assigned a judgement of 'high risk', 'low risk' or 'unclear risk' relating to whether the study was adequate with regard to the risk of bias for each domain's entry. We contacted the authors of trials for additional information on domains judged to be 'unclear'. When authors did not respond within four weeks, we assigned a judgement on the domain based on the available information. We documented agreement between review authors and resolved discrepancies by consensus. </p> </section> <section id="CD007325-sec-0057"> <h4 class="title">Measures of treatment effect</h4> <p>We reported dichotomous variables as risk ratios (RRs) with 95% confidence intervals (CIs), unless the outcome of interest occurred at very low frequency (&lt; 1%), in which case we used the Peto odds ratio. We reported continuous variables as mean differences between treatment groups with 95% CIs. We did not check for skewness of data as both continuous outcomes of interest (mean change in visual acuity and mean change in central retinal thickness) were measured as mean changes from baseline. </p> </section> <section id="CD007325-sec-0058"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the eye for data on visual acuity and macular oedema measurements. The unit of analysis was the individual for ocular adverse events, demographic characteristics, economic data and quality of life data. In all trials, only one eye from each patient was enrolled, and we reviewed the method for selecting the study eye to assess for potential selection bias. </p> </section> <section id="CD007325-sec-0059"> <h4 class="title">Dealing with missing data</h4> <p>We attempted to contact authors for missing data. When authors did not respond within four weeks, we imputed data where possible using available information such as P values or confidence intervals (CIs). </p> </section> <section id="CD007325-sec-0060"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed clinical diversity (variability in the participants, interventions and outcomes studied), methodological diversity (variability in study design and risk of bias) and statistical heterogeneity (variability in the intervention effects being evaluated) by examining study characteristics and forest plots of the results. We used the I<sup>2</sup> statistic to quantify inconsistency across studies and the Chi<sup>2</sup> test to assess statistical heterogeneity for meta‐analysis. We interpreted an I<sup>2</sup> value of 50% or more to be substantial, as this suggests that more than 50% of the variability in effect estimates was due to heterogeneity rather than sampling error (chance). We considered P &lt; 0.10 to represent significant statistical heterogeneity for the Chi<sup>2</sup> test. </p> </section> <section id="CD007325-sec-0061"> <h4 class="title">Assessment of reporting biases</h4> <p>We accessed the primary and secondary outcomes registered on clinicaltrials.gov for each trial to look for possible selective outcome reporting. We did not examine funnel plots for publication bias as fewer than 10 studies were included in the review. Where summary estimates of treatment effect across multiple studies (i.e. more than 10) are included in the future, we will examine funnel plots from each meta‐analysis to assess publication bias. </p> </section> <section id="CD007325-sec-0062"> <h4 class="title">Data synthesis</h4> <p>Where data from three or more trials were available, we considered performing meta‐analysis using a random‐effects model. We considered a fixed‐effect model if synthesising data from fewer than three trials. If significant heterogeneity was found, we reported results in tabular form, rather than performing meta‐analysis. The dichotomous outcome variables were the proportion of patients with at least a 15 letter gain or loss in visual acuity. Continuous outcome variables included the mean changes from baseline in visual acuity and central retinal thickness. </p> <p>Additional dichotomous outcomes were the proportion of patients experiencing each ocular or systemic adverse event, and the proportion requiring additional treatments (e.g. panretinal photocoagulation), at six months and other follow‐up times. We reported the total number of events at six months, in the combined treatment groups and combined control groups. Since the sample size was tailored to the primary outcome, these secondary outcomes may well lack power to detect important differences. We used the Peto odds ratio method to combine data on a given outcome across multiple studies at event rates below 1%, providing there was no substantial imbalance between the treatment and control group sizes. </p> </section> <section id="CD007325-sec-0063"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to conduct subgroup analyses and investigate possible sources of heterogeneity based on type of anti‐VEGF agent, clinical subtype (ischaemic an non‐ischaemic), duration since onset and baseline BCVA. Data were not sufficient to conduct subgroup analyses for this review (only six studies were included and outcome‐specific data were not always available for each study); however, we documented when individual trials noted subgroup differences. If sufficient and comparable data are reported in future updates to this review, we will conduct subgroup analyses based on the criteria listed above. </p> </section> <section id="CD007325-sec-0064"> <h4 class="title">Sensitivity analysis</h4> <p>We considered performing sensitivity analyses to examine how strongly related our review results were to decisions and assumptions that were made during the review. If there were a sufficient number of studies to obtain an informative result, we planned to investigate the impact of studies with lower methodological quality (e.g. domains judged to be inadequate with regard to risk of bias, marked 'high risk' or 'unclear' in the 'Risk of bias' table). We also planned to perform sensitivity analyses if there were any unpublished data or if studies differed with regard to their funding source (e.g. industry‐funded studies). </p> <section id="CD007325-sec-0065"> <h5 class="title">Summary of findings</h5> <p>We produced a 'Summary of findings' tables of the primary and secondary outcomes included in our review for the comparison of anti‐VEGF therapy versus sham injection. We judged the quality of evidence by consensus and assessed each outcome as follows. </p> <p> <ul id="CD007325-list-0004"> <li> <p>High quality: most evidence comes from RCTs at low risk of bias, consistent results with no unexplained heterogeneity, low probability of publication bias, and a large magnitude of effect or an apparent dose‐response gradient. </p> </li> <li> <p>Moderate quality: most evidence comes from RCTs with some limitations. For example, limitations may include an unclear risk of bias in one or several domains, few participants and wide confidence intervals suggesting imprecision of evidence. </p> </li> <li> <p>Low quality: most evidence comes from studies with limitations. For example, limitations may include an unclear or high risk of bias in one or several domains, few studies reporting this outcome, few participants and wide confidence intervals suggesting imprecision of evidence. </p> </li> <li> <p>Very low quality: most evidence comes from studies with major limitations. For example, limitations may include high risk of bias in one or several domains, few studies reporting this outcome and great uncertainty about the estimate. </p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007325-sec-0066" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007325-sec-0066"></div> <section id="CD007325-sec-0067"> <h3 class="title">Description of studies</h3> <section id="CD007325-sec-0068"> <h4 class="title">Results of the search</h4> <p>The electronic search on 10 August 2010 yielded a total of 123 non‐duplicate titles with accompanying abstracts. We screened full‐text articles corresponding to 34 possibly relevant titles and two definitely relevant titles (<a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>; <a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a>), which identified two RCTs comparing an anti‐VEGF treatment to sham injection. There were no RCTs comparing anti‐VEGF agents to observation only. We excluded one trial because it compared treatment with bevacizumab to combined treatment with bevacizumab and timolol‐dorzolamide, with no group that did not receive anti‐VEGF treatment (<a href="./references#CD007325-bbs2-0007" title="ByeonSH , KwonOW , SongJH , KimSE , ParkYS . Prolongation of activity of single intravitreal bevacizumab by adjuvant topical aqueous depressant (Timolol‐Dorzolamide). Graefes Archive for Clinical and Experimental Ophthalmology2009;247(1):35‐42. ">Byeon 2009</a>). Two studies are awaiting classification as they are potentially relevant to this review, yet no results have been made available (<a href="./references#CD007325-bbs2-0011" title="">EBOVER</a>; <a href="./references#CD007325-bbs2-0012" title="HabibabadiH , MoradianS , PiriN , EsfahaniM , AalamiZ , LashayA , et al. Intravitreal bevacizumab vs combination of bevacizumab and triamcinolone vs sham treatment in central retinal vein occlusion. American Academy of Ophthalmology 2008. Conference abstract 271. HabibabadiHF , MoradianS , PiriN , EsfahaniMR , AalamiZ , KarkhanehR , et al. Intravitreal bevacizumab vs combination of bevacizumab and triamcinolone vs sham treatment for central retinal vein occlusion. American Academy of Ophthalmology 2007. Conference abstract 273. ">Habibabadi 2008</a>). </p> <p>An updated electronic search on 29 October 2013 yielded 217 additional non‐duplicate titles with accompanying abstracts. We screened full‐text articles corresponding to 22 possibly relevant titles, of which 18 were pertinent to this review. From these 18 reports we identified four new RCTs comparing an anti‐VEGF treatment to sham injection (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>; <a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>; <a href="./references#CD007325-bbs2-0005" title="KingeB , StordahlPB , ForsaaV , FossenK , HaugstadM , HelgesenOH , et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham‐controlled ROCC Study. American Journal of Ophthalmology2010;150(3):310‐4. ">ROCC 2010</a>). We excluded four reports from three randomised studies which did not include a control or observation group (<a href="./references#CD007325-bbs2-0008" title="CampochiaroPA , HafizG , ShahSM , NguyenQD , YingH , DoDV , et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Molecular Therapy2008;16(4):791‐9. CampochiaroPA , ShahSM , HafizG , QuinlanE , Zimmer‐GllerI , NguyenQD , et al. Ranibizumab for macular edema due to retinal vein occlusions. Investigative Ophthalmology and Visual Science2007; Vol. 48. ARVO E‐abstract 1545. ">Campochiaro 2008</a>; <a href="./references#CD007325-bbs2-0009" title="DingX , LiJ , HuX , YuS , PanJ , TangS . Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion. Retina (Philadelphia, Pa.)2011;31(5):838‐45. ">Ding 2011</a>; <a href="./references#CD007325-bbs2-0010" title="WangH , LiX , WangY , ZhangZ , LiM , SuX , ZhuJ . Intravitreal injection of bevacizumab alone or with triamcinolone acetonide for treatment of macular edema caused by central retinal vein occlusion. International Journal of Ophthalmology2011;4(1):89‐94. ">Wang 2011</a>) (See <a href="#CD007325-fig-0001">Figure 1</a>). There were no RCTs comparing anti‐VEGF agents to observation. </p> <div class="figure" id="CD007325-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Results from searching for studies for inclusion in the review (as of 29 October 2013)." data-id="CD007325-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_n/nCD007325-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Results from searching for studies for inclusion in the review (as of 29 October 2013).</p> </div> </div> </div> </section> <section id="CD007325-sec-0069"> <h4 class="title">Included studies</h4> <p>We found six trials that met our inclusion criteria (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>; <a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>; <a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>; <a href="./references#CD007325-bbs2-0005" title="KingeB , StordahlPB , ForsaaV , FossenK , HaugstadM , HelgesenOH , et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham‐controlled ROCC Study. American Journal of Ophthalmology2010;150(3):310‐4. ">ROCC 2010</a>; <a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a>). These investigated four anti‐VEGF agents in comparison to sham injection: VEGF Trap Eye (Aflibercept), bevacizumab (Avastin), ranibizumab (Lucentis) and Pegaptanib sodium (Macugen). The study design, treatments, doses and duration of treatment are summarised in the following table. The table <a href="./references#CD007325-sec-0121" title="">Characteristics of included studies</a> details a full summary of each of these trials. </p> <section id="CD007325-sec-0070"> <h5 class="title">Table: Summary of included studies</h5> <p> <div class="table" id="CD007325-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study design</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment group 1</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment group 2</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control group</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of injections</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment period</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phase III dmRCT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VEGF Trap‐Eye 2.0 mg (n = 114)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham injection (n = 74)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phase III dmRCT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ranibizumab 0.3 mg (n = 132)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ranibizumab 0.5 mg (n = 130)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham injection (n = 130)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phase III dmRCT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg (n = 30)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham injection (n = 30)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phase III dmRCT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VEGF Trap‐Eye 2.0 mg (n = 106)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham injection (n = 71)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 + PRN</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007325-bbs2-0005" title="KingeB , StordahlPB , ForsaaV , FossenK , HaugstadM , HelgesenOH , et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham‐controlled ROCC Study. American Journal of Ophthalmology2010;150(3):310‐4. ">ROCC 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phase III dmRCT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ranibizumab 0.5 mg (n = 16)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham injection (n = 16)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 + 3 (PRN)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phase II dmRCT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pegaptanib sodium 0.3 mg (n = 33)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pegaptanib sodium 1.0 mg (n = 33)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham injection (n = 32)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 weeks</p> </td> </tr> </tbody> </table> </div> </p> <p>PRN = pro re nata (as the circumstances require)<br/> dmRCT = double‐masked randomised controlled trial </p> </section> <section id="CD007325-sec-0071"> <h5 class="title">Extension studies</h5> <p>In an open‐label, six‐month extension of the bevacizumab trial (<a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>), all participants (n = 60, 100%) in both the sham control and bevacizumab 1.25 mg groups were treated with bevacizumab 1.25 mg every six weeks, to 12 months. </p> <p>In an open‐label, six‐month observation period (i.e. months 7 to 12) participants in the <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a> trial were reviewed monthly and offered ranibizumab if they met retreatment criteria including central retinal thickness &gt; 250 or BCVA &lt; 6/12. Those in the original treatment groups received either 0.3 mg or 0.5 mg ranibizumab, according to their original randomisation, whilst participants in the original sham control group received 0.5 mg ranibizumab. Of 392 participants randomised at baseline, 363 (92.6%) completed the study to six months, and 349 (89.0%) completed the open‐label extension study to 12 months. A further 12‐month, open‐label extension (i.e. months 13 onwards), the HORIZON trial, explored safety and efficacy in 304 (77.5%) of those originally recruited to the CRUISE trial. Participants were seen at least every three months and offered 0.5 mg ranibizumab if they met retreatment criteria. During the study, ranibizumab was approved by the FDA for the treatment of retinal vein occlusion and according to the protocol, all participants were discontinued from the study by 30 days after the approval date. The duration of follow‐up in the HORIZON trial was therefore variable, with a mean of 14 months (standard deviation (SD) 4.7, range 1 to 24 months), and missing outcome data at 24 months were considerable, with the consequent potential for significant attrition bias in the available results. </p> <p>In an open‐label, six‐month extension of the <a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a> trial (i.e. months 7 to 12), all participants were offered 2.0 mg aflibercept (VEGF Trap‐Eye) monthly as needed, according to retreatment criteria. One hundred and sixty‐four (86.8%) of the participants randomised at baseline completed 52 weeks. </p> </section> <section id="CD007325-sec-0072"> <h5 class="title">Baseline characteristics</h5> <p>The six trials included patients with broadly similar baseline characteristics, which are summarised in the table below. There was some difference in the proportion of recruited patients who were ischaemic at baseline, with negligible ischaemia at baseline in patients recruited to <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a> and <a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a>. The mean age and percentage of male participants was similar across the six trials. The mean time between occlusive event and study entry was also broadly similar across the groups. The baseline mean BCVA measured in ETDRS letters was broadly similar between studies, ranging from a mean of 52 letters in <a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a> (Snellen approximately 6/30 or 20/100) to 43 letters (Snellen approximately 6/42 or 20/138) in the smaller of the ranibizumab trials (<a href="./references#CD007325-bbs2-0005" title="KingeB , StordahlPB , ForsaaV , FossenK , HaugstadM , HelgesenOH , et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham‐controlled ROCC Study. American Journal of Ophthalmology2010;150(3):310‐4. ">ROCC 2010</a>). The percentage of patients with a poor presenting BCVA of less than 35 letters (Snellen approximately 6/60 or 20/200) ranged from 17% (<a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>) to 32% (<a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>). The mean baseline central retinal thickness (CRT) was broadly similar across the six trials, ranging between 619 μm (<a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a>) and 721 μm (<a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>). </p> </section> <section id="CD007325-sec-0073"> <h5 class="title">Table: Summary of baseline characteristics</h5> <p> <div class="table" id="CD007325-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of CRVO‐MO</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>% Ischaemic</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean age (years)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>% Male</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline mean VA (letters)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>% BCVA less than 35 letters (6/60)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean CRT (μm)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 9 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.5% (29/187) ischaemic</p> <p>16.6% (31/187) undetermined</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 2.40 months (SD 2.80)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50.0 (SD 14.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.6%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>665.8 (SD 239.8)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5% (2/392)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 3.3 months</p> <p>Median 2 months (range 0 to 27)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.1 (14.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>680 (242) to 689 (253)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.7% (7/60)*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 8.8 weeks (SD 5.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.1 (SD 15.5) letters</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>721 (SD 269)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 9 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.2% (14/171) ischaemic</p> <p>8.2% (14/171) undetermined</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 82 days (SD 85)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52.2 (SD 15.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>665.5 (SD 231.0)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007325-bbs2-0005" title="KingeB , StordahlPB , ForsaaV , FossenK , HaugstadM , HelgesenOH , et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham‐controlled ROCC Study. American Journal of Ophthalmology2010;150(3):310‐4. ">ROCC 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.6% (5/32)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 78 days (range 10 to 163)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (SD 22)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>625 (SD 159)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0% (0/98)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 80 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>619 to 675</p> </td> </tr> </tbody> </table> </div> </p> <p>* Personal communication<br/> SD = standard deviation<br/> VA = visual acuity, measured in ETDRS letters<br/> CRT = central retinal thickness </p> </section> </section> <section id="CD007325-sec-0074"> <h4 class="title">Excluded studies</h4> <p>We excluded four randomised studies including an anti‐VEGF intervention group because they did not include a sham control or observation arm. One non‐masked trial randomised 20 patients with CRVO macular oedema to receive 0.3 mg (n = 10) or 0.5 mg (n = 10) ranibizumab given monthly for three months (<a href="./references#CD007325-bbs2-0008" title="CampochiaroPA , HafizG , ShahSM , NguyenQD , YingH , DoDV , et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Molecular Therapy2008;16(4):791‐9. CampochiaroPA , ShahSM , HafizG , QuinlanE , Zimmer‐GllerI , NguyenQD , et al. Ranibizumab for macular edema due to retinal vein occlusions. Investigative Ophthalmology and Visual Science2007; Vol. 48. ARVO E‐abstract 1545. ">Campochiaro 2008</a>). In a subsequent extension trial to 24 months, patients were reviewed every two months and treated with the same dose of ranibizumab as their initial treatment assignment, if retreatment criteria were met (<a href="./references#CD007325-bbs2-0023" title="CampochiaroPA , HafizG , ChannaR , ShahSM , NguyenQD , YingH , et al. Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: two‐year outcomes. Ophthalmology2010;117(12):2387‐94. ">Campochiaro 2010</a>). A second trial compared treatment with bevacizumab to combined treatment with bevacizumab and timolol‐dorzolamide, without comparison to a sham injection or observation group. This trial combined patients with both BRVO and CRVO, and the small sample size precluded analysis of CRVO macular oedema specifically (<a href="./references#CD007325-bbs2-0007" title="ByeonSH , KwonOW , SongJH , KimSE , ParkYS . Prolongation of activity of single intravitreal bevacizumab by adjuvant topical aqueous depressant (Timolol‐Dorzolamide). Graefes Archive for Clinical and Experimental Ophthalmology2009;247(1):35‐42. ">Byeon 2009</a>). A third open‐label study randomised patients with CRVO macular oedema to receive intravitreal injection of either 4 mg preservative‐free triamcinolone acetonide (n = 16) or 1.25 mg bevacizumab (n = 16) at baseline, with subsequent 'as required' injections from three months (<a href="./references#CD007325-bbs2-0009" title="DingX , LiJ , HuX , YuS , PanJ , TangS . Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion. Retina (Philadelphia, Pa.)2011;31(5):838‐45. ">Ding 2011</a>). A fourth open‐label study randomised patients with CRVO macular oedema to a single injection of either 1.25 mg bevacizumab or to combination therapy with 1.25 mg bevacizumab plus 2.0 mg triamcinolone acetonide, with follow‐up over 12 weeks (<a href="./references#CD007325-bbs2-0010" title="WangH , LiX , WangY , ZhangZ , LiM , SuX , ZhuJ . Intravitreal injection of bevacizumab alone or with triamcinolone acetonide for treatment of macular edema caused by central retinal vein occlusion. International Journal of Ophthalmology2011;4(1):89‐94. ">Wang 2011</a>). (See the <a href="./references#CD007325-sec-0122" title="">Characteristics of excluded studies</a> table for further details). </p> <p>We did not conduct a separate electronic search for study designs less rigorous than the randomised controlled trial. We identified numerous interventional case series and case reports and summarised them in tables in the first publication of this review (<a href="./references#CD007325-bbs2-0091" title="BraithwaiteT , NanjiAA , GreenbergPB . Anti‐vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion. Cochrane Database of Systematic Reviews2010, Issue 10. [DOI: 10.1002/14651858.CD007325] ">Braithwaite 2010</a>). These studies did not meet the inclusion criteria for the systematic review, and these tables were not updated or included in the current review. </p> </section> </section> <section id="CD007325-sec-0075"> <h3 class="title">Risk of bias in included studies</h3> <p>The six included studies had a low risk of bias in a majority of domains (see <a href="#CD007325-fig-0002">Figure 2</a> and <a href="#CD007325-fig-0003">Figure 3</a>). In all studies one eye was enrolled in the study per participant. In <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a> the authors specified that where both eyes met the inclusion criteria, the eye with the worse BCVA at screening was selected. In <a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a> and <a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a> the patient was excluded if both eyes had a retinal vein occlusion at baseline. In <a href="./references#CD007325-bbs2-0005" title="KingeB , StordahlPB , ForsaaV , FossenK , HaugstadM , HelgesenOH , et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham‐controlled ROCC Study. American Journal of Ophthalmology2010;150(3):310‐4. ">ROCC 2010</a> patients were only recruited to the study if they had unilateral CRVO macular oedema. Whilst one eye per patient was included in the remaining two trials, <a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a> and <a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>, no statement regarding the method of selection of the study eye was given to cover the uncommon event that both eyes met the eligibility criteria. </p> <div class="figure" id="CD007325-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD007325-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_n/nCD007325-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD007325-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007325-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_n/nCD007325-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD007325-sec-0076"> <h4 class="title">Allocation</h4> <p>We judged there to be a low risk of bias in random sequence generation in three studies (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a><a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>; <a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a>). These studies all reported a centralised randomisation method. We considered the risk of bias 'unclear' in the other three studies (<a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012;</a><a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>; <a href="./references#CD007325-bbs2-0005" title="KingeB , StordahlPB , ForsaaV , FossenK , HaugstadM , HelgesenOH , et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham‐controlled ROCC Study. American Journal of Ophthalmology2010;150(3):310‐4. ">ROCC 2010</a>). We gave a judgement of unclear risk of bias where the study investigators did not explicitly report the process of random sequence generation, and either did not respond to a request for further information, or did not provide sufficient additional explanation via personal communication. </p> <p>We judged there to be a low risk of bias in allocation concealment in three studies (<a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>; <a href="./references#CD007325-bbs2-0005" title="KingeB , StordahlPB , ForsaaV , FossenK , HaugstadM , HelgesenOH , et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham‐controlled ROCC Study. American Journal of Ophthalmology2010;150(3):310‐4. ">ROCC 2010</a>; <a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a>). We considered the risk of bias to be low in studies that explicitly reported the method of protection of the allocation sequence between the time of randomisation and of treatment assignment to injection or sham injection. For example, if the medication kits were identical in appearance and identified by randomisation number only, and if the allocation was conveyed to the injecting ophthalmologist by the study co‐ordinator, or another third party, in a way that did not inform the injecting ophthalmologist of the allocation until the time of the injection procedure, then we considered the risk of bias low. When sealed, opaque envelopes drawn by staff not involved in patient treatment or follow‐up were used to conceal allocation until the first day of injection, we judged the risk of bias to be low, even if the envelopes were not sequentially numbered based on the randomisation code, although we note that methods utilising envelopes may be subject to manipulation. We felt the risk of bias in this domain was unclear in the remaining three studies (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>; <a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>), in which the method of concealment of the allocations was not described explicitly. </p> </section> <section id="CD007325-sec-0077"> <h4 class="title">Blinding</h4> <p>We considered all six studies to have a low risk of bias in this domain. In these studies, the participants, examining ophthalmologists and other clinical examiners were masked to the treatment allocation. In addition, in the aflibercept trial (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>), pegaptanib sodium trial (<a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a>) and the <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a> trial, grading of OCT and FFA images was done by an independent grading centre. The ophthalmologists performing the intravitreal injections, who performed either a sham injection or a drug injection, were not involved in reviewing the participants at their follow‐up assessments. In all studies an attempt was made to mask patients randomised to the control group by treating them similarly to those in the treatment groups, except that the hub of a syringe was placed against the injection site and the plunger depressed to mimic an injection, without globe penetration (i.e. sham injection). It is unclear whether sham injection effectively masks patients to their treatment allocation, given that patients sometimes report 'feeling' the needle despite topical anaesthesia, and that the injection can cause a subconjunctival haemorrhage which would not necessarily be expected with a sham injection. However, a majority of the outcomes in these studies are relatively objective measures, so that even if a patient suspected their assignment this would be unlikely to bias the outcome data. </p> </section> <section id="CD007325-sec-0078"> <h4 class="title">Incomplete outcome data</h4> <p>We considered there to be a low risk of attrition bias in one study reporting no loss to follow‐up (<a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>). We also would have considered the risk of bias to be low if the losses to follow‐up were small and balanced between the groups, with analysis by intention‐to‐treat, or if imputation methods that provide valid type 1 error rates under explicitly stated assumptions were used to take moderate missing data into account. </p> <p>Where we considered the losses to be slightly more considerable as a proportion of the total sample (an issue with small studies), or where we felt that losses to follow‐up were unbalanced between groups, but where the investigators reported reasons for losses, we considered the risk of bias 'unclear' (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>; <a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>; <a href="./references#CD007325-bbs2-0005" title="KingeB , StordahlPB , ForsaaV , FossenK , HaugstadM , HelgesenOH , et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham‐controlled ROCC Study. American Journal of Ophthalmology2010;150(3):310‐4. ">ROCC 2010</a>; <a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a>). Unbalanced loss of patients with potentially more severe and visually significant disease from the sham group in these trials might have introduced bias, reducing any apparent benefit associated with anti‐VEGF therapy. We also considered the risk of bias 'unclear' where investigators did not account for missing data, performing only a 'per protocol' analysis (<a href="./references#CD007325-bbs2-0005" title="KingeB , StordahlPB , ForsaaV , FossenK , HaugstadM , HelgesenOH , et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham‐controlled ROCC Study. American Journal of Ophthalmology2010;150(3):310‐4. ">ROCC 2010</a>), restricted to those participants who fulfilled the criteria for eligibility, received all prescribed interventions and attended all outcome assessments. Non‐random loss of participants is better handled through analysis by the intention‐to‐treat approach, in which data are analysed according to randomisation group, regardless of whether the participants received or adhered to their allocated intervention, as this provides fair comparisons among the groups. </p> <p>Where investigators accounted for losses to follow‐up or unbalanced missing data using the last‐observation‐carried‐forward (LOCF) method, without performing sensitivity analyses to assess the impact of assumptions about the method of accounting for missing data on trial outcomes, we also considered the risk 'unclear' (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>; <a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>). The LOCF method limits the number of patients eliminated from the analysis. However, it assumes that patients do not change from their last follow‐up (i.e. they could improve or get worse and in either case this would not be captured). Treating missing data as if there has been no change from a previous visit generally yields a conservative estimate of treatment effect. If patients who are given treatment drop out because they get worse or experience harmful side effects then the LOCF methods may over‐report efficacy or under‐report harmful safety problems. </p> </section> <section id="CD007325-sec-0079"> <h4 class="title">Selective reporting</h4> <p>We accessed ClinicalTrials.gov to review the prespecified primary and secondary outcomes for the trials, where these were available. We considered there to be a low risk of selective reporting bias in all six studies (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>; <a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>; <a href="./references#CD007325-bbs2-0005" title="KingeB , StordahlPB , ForsaaV , FossenK , HaugstadM , HelgesenOH , et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham‐controlled ROCC Study. American Journal of Ophthalmology2010;150(3):310‐4. ">ROCC 2010</a>; <a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a>), in which the main prespecified primary and secondary outcomes were reported. In <a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>, an additional secondary outcome of mean change in BCVA was added in the published report. In <a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>, two additional secondary outcomes were reported: the proportion of eyes progressing to ocular neovascularisation and the change in total score on the National Eye Institute 25‐item Visual Function Questionnaire (NEI VFQ‐25) from baseline. In <a href="./references#CD007325-bbs2-0005" title="KingeB , StordahlPB , ForsaaV , FossenK , HaugstadM , HelgesenOH , et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham‐controlled ROCC Study. American Journal of Ophthalmology2010;150(3):310‐4. ">ROCC 2010</a>, the investigators prespecified that they would include mean change from baseline in the NEI VFQ‐25 near activities subscale as a secondary outcome, but did not include this in their published report. However, as the subscale on this instrument is not a validated outcome measure, we felt that failure to report these results had no impact on the key outcome measures of interest. The ClinicalTrials.gov entry for <a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a> did not include prespecified outcome measures. However, all outcomes that would be expected were included, and both positive and negative results were reported without apparent bias, so although we were not able to exclude the possibility of selective reporting, we considered the study 'low risk' in this domain. Four studies did not report measures of variance for continuous variables including mean change in best‐corrected visual acuity from baseline and mean change in central retinal thickness from baseline (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012;</a><a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>; <a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a>); unpublished data were provided for the bevacizumab trial (personal communication). </p> </section> <section id="CD007325-sec-0080"> <h4 class="title">Other potential sources of bias</h4> <p>We considered the risk of bias to be low in three studies where no other threats to validity were identified, or where we considered potential sources of bias to be very small (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>; <a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a>). We considered the risk of bias to be 'unclear' in three studies where protocol violations were reported, resulting from recruitment of small numbers of patients who either did not meet the prespecified inclusion criteria, or who did not receive all planned treatment (<a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>; <a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>; <a href="./references#CD007325-bbs2-0005" title="KingeB , StordahlPB , ForsaaV , FossenK , HaugstadM , HelgesenOH , et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham‐controlled ROCC Study. American Journal of Ophthalmology2010;150(3):310‐4. ">ROCC 2010</a>). </p> </section> </section> <section id="CD007325-sec-0081"> <h3 class="title" id="CD007325-sec-0081">Effects of interventions</h3> <p>See: <a href="./full#CD007325-tbl-0001"><b>Summary of findings for the main comparison</b> </a> </p> <section id="CD007325-sec-0082"> <h4 class="title">Primary outcome</h4> <section id="CD007325-sec-0083"> <h5 class="title">Gain of at least 15 letters best‐corrected visual acuity at six months</h5> <p>Five studies reported this outcome (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>; <a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>; <a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>; <a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a>), and unpublished data were provided by study investigators for the sixth study (<a href="./references#CD007325-bbs2-0005" title="KingeB , StordahlPB , ForsaaV , FossenK , HaugstadM , HelgesenOH , et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham‐controlled ROCC Study. American Journal of Ophthalmology2010;150(3):310‐4. ">ROCC 2010</a>). The table below summarises and compares the data across the six randomised controlled trials (RCTs) at six months. The proportion gaining 15 letters or more of visual acuity at six months ranged from 12.3% to 28.1% in the sham groups, and from 36.4% to 60.2% in the treatment groups. Data from six trials were included in the meta‐analysis. Meta‐analysis indicated that patients receiving intravitreal anti‐vascular endothelial growth factor (anti‐VEGF) treatment were 2.71 times more likely to gain 15 letters or more of visual acuity at six months compared to patients treated with sham injections, and the 95% confidence interval (CI) suggested a statistically significant effect (RR 2.71; 95% CI 2.10 to 3.49) (see <a href="./references#CD007325-fig-0007" title="">Analysis 1.1</a>; <a href="#CD007325-fig-0004">Figure 4</a>). There was no significant statistical heterogeneity (I<sup>2</sup> = 10%), and also no significant difference between the different anti‐VEGF subgroups (I<sup>2</sup> = 11.7%). This demonstrates a clinically significant gain in visual acuity at six months associated with anti‐VEGF therapy. </p> <div class="figure" id="CD007325-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: Anti‐VEGF versus sham intravitreal injection, outcome: 1.1 Gain of 15 letters or more at 6 months." data-id="CD007325-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_n/nCD007325-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: Anti‐VEGF versus sham intravitreal injection, outcome: 1.1 Gain of 15 letters or more at 6 months. </p> </div> </div> </div> <p> <div class="table" id="CD007325-tblf-0003"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment group 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>% &gt; 15 letters gain at 6 months (n)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment group 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>% &gt; 15 letters gain at 6 months (n)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>% &gt; 15 letters gain at 6 months (n)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VEGF Trap‐Eye 2.0 mg (n = 114)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.1 (64/114)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham injection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.3 (9/73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ranibizumab 0.3 mg (n = 132)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.2 (61/132)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ranibizumab 0.5 mg (n = 130)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.7 (62/130)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham injection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.9 (22/130)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.0001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg (n = 30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60.0 (18/30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham injection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.0 (6/30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.003</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VEGF Trap‐Eye 2.0 mg (n = 106)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60.2 (62/103)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham injection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.1 (15/68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.0001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007325-bbs2-0005" title="KingeB , StordahlPB , ForsaaV , FossenK , HaugstadM , HelgesenOH , et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham‐controlled ROCC Study. American Journal of Ophthalmology2010;150(3):310‐4. ">ROCC 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ranibizumab 0.5 mg (n = 16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53.3 (8/15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham injection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.3 (2/14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pegaptanib sodium 0.3 mg (n = 33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.4 (12/33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pegaptanib sodium 1.0 mg (n = 33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.4 (13/33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham injection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.1 (9/32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.35</p> </td> </tr> </tbody> </table> </div> </p> <p>Only one RCT reported 12‐month outcomes for 15‐letter gain in visual acuity, comparing treatment with 2 mg intravitreal aflibercept versus sham control, using PRN (as needed) dosing between months 6 and 12 (<a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>). Meta‐analysis was therefore not performed. The proportion receiving aflibercept who gained 15 letters or more was largely maintained between months 6 and 12, at 60.2%. A mean 2.5 injections (standard deviation (SD) 1.7) were required during the PRN phase. The proportion gaining 15 letters of visual acuity improved in those randomised to sham injection who received PRN aflibercept between 6 and 12 months, from 22.1% to 32.4% (<a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>), but remained significantly worse than those randomised to aflibercept (P = 0.0004). </p> <p>In the three open‐label extension studies the gain in visual acuity seen at six months in those treated with anti‐VEGF agents was also largely maintained at 12 months (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>; <a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>). Fifteen letters or more of visual acuity was gained at 12 months by 55.3% (63/114) of those treated with aflibercept monthly for six months then PRN with monthly reassessment for a further six months (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>); by 60% (18/30) of those treated with bevacizumab every six weeks for 12 months (<a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>); and by 47.0% (62/132) and 50.8% (66/130) of those treated with 0.3 mg and 0.5 mg ranibizumab, respectively, every month for six months then PRN with monthly reassessment for a further six months (<a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>). Patients randomised to sham injection in these three trials crossed over to treatment with anti‐VEGF from months 7 to 12, and in all sham/anti‐VEGF groups the proportion gaining 15 letters or more at 12 months was higher than it had been at six months prior to treatment with anti‐VEGF. Specifically, 15 letters or more gain in BCVA was reported in 30.1% (22/73) receiving delayed 2.0 mg aflibercept PRN for six months (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>), 33.1% (43/130) receiving delayed 0.5 mg ranibizumab PRN for six months (<a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>) and 33.3% (10/30) receiving delayed 1.25 mg bevacizumab every six weeks for six months (<a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>). However, in all three trials the sham/anti‐VEGF cross‐over groups remained significantly worse with respect to this primary outcome than the groups initially randomised to anti‐VEGF treatment. </p> <p>Subgroup comparison of patients with baseline ischaemic central retinal vein occlusion (CRVO) macular oedema versus non‐ischaemic CRVO macular oedema, defined as over 10 disc areas of retinal non‐perfusion on a seven standard field fluorescein angiogram, was reported in one trial (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>). The proportion of eyes with baseline ischaemia who gained 15 letters at six months was 51.4% versus 4.3% in those treated with aflibercept and sham respectively (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>). The proportion of eyes without ischaemia at baseline who gained 15 letters at six months was 58.4% versus 16.0% in those treated with aflibercept and sham, respectively. At 52 weeks, the proportion gaining 15 letters or more of visual acuity following anti‐VEGF treatment was largely maintained in both ischaemic and non‐ischaemic treatment groups, at 48.6% and 58.4%, respectively. Following cross‐over PRN treatment of the sham group from months 7 to 12, the proportion gaining 15 letters or more improved in both ischaemic and non‐ischaemic sham randomised patients, to 30.4% and 30.0%. This suggests a beneficial effect of anti‐VEGF treatment in both patients with ischaemic CRVO and with non‐ischaemic CRVO, and a lesser benefit to both ischaemic and non‐ischaemic subgroups if treatment is delayed by six months. </p> <p>Subgroup comparison of patients randomised to receive treatment within or beyond two months of diagnosis was performed in two trials (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>). The proportion of patients treated with aflibercept who gained 15 letters or more at six months was 64.1% versus 42.9% in those receiving first aflibercept treatment within or later than two months of diagnosis, respectively (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>). Similarly, in the GALILEO study, a 15 letter gain was seen in 70.9% versus 50.0% treated with aflibercept within or beyond two months of diagnosis, respectively (<a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>). This suggests a more beneficial effect of anti‐VEGF treatment when commenced early. </p> <p>Subgroup comparison of patients with a baseline BCVA of 6/60 (20/200) or worse was performed in one trial (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>). The proportion gaining 15 letters or more at six months was 67.9% versus 16.7% in the aflibercept versus sham groups with a baseline visual acuity of 6/60 (20/200) or worse, and 52.3% versus 10.9% in the aflibercept versus sham treated groups with a baseline visual acuity better than 6/60. This suggests that anti‐VEGF treatment is beneficial even with a very poor presenting visual acuity. </p> </section> </section> <section id="CD007325-sec-0084"> <h4 class="title">Secondary outcomes</h4> <section id="CD007325-sec-0085"> <h5 class="title">Loss of 15 letters or more best‐corrected visual acuity at six months</h5> <p>Four studies reported this outcome (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>; <a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>; <a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a>), and unpublished data were provided by study investigators for a fifth study (<a href="./references#CD007325-bbs2-0005" title="KingeB , StordahlPB , ForsaaV , FossenK , HaugstadM , HelgesenOH , et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham‐controlled ROCC Study. American Journal of Ophthalmology2010;150(3):310‐4. ">ROCC 2010</a>). The table below summarises and compares the data across the five RCTs. The proportion losing 15 letters of visual acuity at six months ranged from 15.4% to 31.2% in the sham groups, and from 1.8% to 13.3% in the treatment groups. We included data from all five studies in the meta‐analysis. Meta‐analysis suggested that patients receiving intravitreal anti‐VEGF treatment had an 80% lower risk of losing 15 letters of visual acuity at six months compared to patients receiving a sham injection (RR 0.20; 95% CI 0.12 to 0.34) and the 95% CI suggested a statistically significant effect (see <a href="./references#CD007325-fig-0008" title="">Analysis 1.2</a>; <a href="#CD007325-fig-0005">Figure 5</a>). There was no significant statistical heterogeneity (I<sup>2</sup> = 0%) and also no significant difference between the different anti‐VEGF subgroups (I<sup>2</sup> = 0%). This represents a clinically significant benefit of anti‐VEGF therapy at six months. </p> <div class="figure" id="CD007325-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: Anti‐VEGF versus sham intravitreal injection, outcome: 1.2 Loss of 15 letters or more at 6 months." data-id="CD007325-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_n/nCD007325-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: Anti‐VEGF versus sham intravitreal injection, outcome: 1.2 Loss of 15 letters or more at 6 months. </p> </div> </div> </div> <p> <div class="table" id="CD007325-tblf-0004"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment group 1</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>% &gt; 15 letters loss at 6 months</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment group 2</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>% &gt; 15 letters loss at 6 months</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control group</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>% &gt; 15 letters loss at 6 months</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VEGF Trap‐Eye 2.0 mg (n = 114)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8% (2/114)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham injection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.4% (20/73)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ranibizumab 0.3 mg (n = 132)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.8% (5/132)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ranibizumab 0.5 mg (n = 130)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5% (2/130)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham injection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.4% (20/130)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.005</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg (n = 30)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.7% (2/30)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham injection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.3% (7/30)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.15</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VEGF Trap‐Eye 2.0 mg (n = 106)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham injection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007325-bbs2-0005" title="KingeB , StordahlPB , ForsaaV , FossenK , HaugstadM , HelgesenOH , et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham‐controlled ROCC Study. American Journal of Ophthalmology2010;150(3):310‐4. ">ROCC 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ranibizumab 0.5 mg (n = 16)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.3% (2/15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham injection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.6% (4/14)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pegaptanib sodium 0.3 mg (n = 33)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.1% (3/33)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pegaptanib sodium 1.0 mg (n = 33)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.1% (2/33)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham injection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.2% (10/32)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03</p> </td> </tr> </tbody> </table> </div> </p> <p>Only one trial reported 12‐month outcomes and so we did not perform meta‐analysis of this outcome at 12 months (<a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>). Loss of 15 letters or more visual acuity at 12 months developed in 1% (n = 1) of the treatment group versus 14.7% (n = 10) of the sham group (<a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>). </p> <p>In the three open‐label extension trials the number of patients treated with anti‐VEGF therapy who lost 15 letters or more of visual acuity remained stable (<a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>; <a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>), or worsened slightly (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>), between months 6 and 12. Specifically, 6.7% (2/30) treated with an additional six months of bevacizumab six‐weekly (<a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>), 5.3% (6/114) treated with an additional six months of aflibercept PRN <a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>, 3.8% (5/132) treated with an extra six months of 0.3 mg ranibizumab PRN, and 2.3% (3/130) treated with an extra six months of 0.5 mg ranibizumab PRN (<a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>) had &gt; 15 letters loss at 12 months. With six‐month delayed anti‐VEGF treatment, fewer patients in the sham cross‐over groups had &gt; 15 L vision loss at 12 months compared to their six‐month outcomes. Specifically, 6.7% (2/30) (<a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>), 10.0% (13/130) (<a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>) and 15.1% (11/73) (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>) of sham/anti‐VEGF cross‐over patients had more than 15 letters vision loss at 12 months, suggesting a beneficial effect of delayed anti‐VEGF therapy. </p> </section> <section id="CD007325-sec-0086"> <h5 class="title">Mean change in best‐corrected visual acuity at six months</h5> <p>All six studies reported this outcome, but only three reported measures of dispersion (standard deviation or 95% CI) (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>; <a href="./references#CD007325-bbs2-0005" title="KingeB , StordahlPB , ForsaaV , FossenK , HaugstadM , HelgesenOH , et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham‐controlled ROCC Study. American Journal of Ophthalmology2010;150(3):310‐4. ">ROCC 2010</a>). Unpublished data from a fourth study were provided by the investigators (<a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>). The table below summarises and compares the data across the six RCTs. The mean change in best‐corrected visual acuity letter score at six months ranged from a gain of 3.3 letters to a loss of 4.0 letters in the sham groups, and from a gain of 7.1 letters to a gain of 18.0 letters in the treatment groups. In all studies, the greatest gain in BCVA was seen within one to two months of treatment with the anti‐VEGF agents, with maintenance or more gradual improvement thereafter to six months. The mean difference (MD) between anti‐VEGF and sham was 15.23 letters (95% CI 11.57 to 18.89) at six months. Although the statistical heterogeneity was considerable (I<sup>2</sup> = 63%), we combined data in meta‐analysis because the direction of effect was the same for all trials (<a href="./references#CD007325-fig-0009" title="">Analysis 1.3</a>). </p> <p> <div class="table" id="CD007325-tblf-0005"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment group 1</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in BCVA (letters)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment group 2</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in BCVA (letters)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control group</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in BCVA (letters)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VEGF Trap‐Eye 2.0 mg (n = 114)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+17.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham injection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐4.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ranibizumab 0.3 mg (n = 132)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+12.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ranibizumab 0.5 mg (n = 130)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+14.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham injection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+0.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.0001</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg (n = 30)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+14.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham injection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VEGF Trap‐Eye 2.0 mg (n = 106)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+18.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham injection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+3.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.0001</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007325-bbs2-0005" title="KingeB , StordahlPB , ForsaaV , FossenK , HaugstadM , HelgesenOH , et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham‐controlled ROCC Study. American Journal of Ophthalmology2010;150(3):310‐4. ">ROCC 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ranibizumab 0.5 mg (n = 16)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+12.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham injection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.01</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pegaptanib sodium 0.3 mg (n = 33)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+7.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pegaptanib sodium 1.0 mg (n = 33)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+9.9 L</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham injection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02 and 0.09</p> </td> </tr> </tbody> </table> </div> </p> <p>Only one trial reported change in mean BCVA at 12 months and so meta‐analysis was not performed (<a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>). The significant difference between treatment and sham groups seen at 24 weeks was maintained to 52 weeks, with a respective gain from baseline in BCVA of 16.9 letters and 3.8 letters (P &lt; 0.0001). </p> <p>In the three open‐label PRN extension studies the mean gain in BCVA from baseline seen at six months in those treated with anti‐VEGF agents was also largely maintained at 12 months (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>; <a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>). The mean gain in the treatment groups was 16.2 letters (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>), 16.1 letters (<a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>) and 13.9 letters in those treated with both 0.3 mg and 0.5 mg ranibizumab (<a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>). Patients randomised to sham injection in these three trials crossed over to treatment with anti‐VEGF from months 7 to 12, and in all sham/anti‐VEGF groups the mean gain in BCVA at 12 months was higher than it had been at six months prior to treatment with anti‐VEGF. Specifically, a BCVA gain of 3.8 letters from baseline was reported in those receiving six‐month delayed 2.0 mg aflibercept PRN for six months (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>), a gain of 7.3 letters was reported in those receiving delayed 0.5 mg ranibizumab PRN for six months (<a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>), and a gain of 4.6 letters was reported in those receiving delayed 1.25 mg bevacizumab every six weeks for six months (<a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>). However, in all three trials the sham/anti‐VEGF cross‐over groups remained significantly worse with respect to this outcome than the groups initially randomised to anti‐VEGF treatment, with P values for comparison between groups at 12 months of P &lt; 0.001 (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>), P &lt; 0.001 (<a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>) and P &lt; 0.05 (<a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>). Only one study, the HORIZON trial, considered longer‐term acuity outcomes, in 304 patients (87%) who completed the 12‐month CRUISE trial (<a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>). Patients originally randomised to sham (n = 98), 0.3 mg ranibizumab (n = 107) and 0.5 mg ranibizumab (n = 99) were eligible for PRN treatment with 0.5 mg ranibizumab during months 12 to 24, were typically reviewed every three months and received a mean of 2.9, 3.8 and 3.5 injections, respectively. At the end of 24 months of treatment in total, the mean BCVA gain from baseline was 7.6 letters, 8.2 letters and 12.0 letters in the sham/0.5 mg, 0.3 mg/0.5 mg and 0.5 mg groups, respectively. </p> <p>Subgroup analysis in anti‐VEGF treatment groups, based on disease duration, was performed in three studies (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>; <a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>). Patients treated with bevacizumab within 90 days improved by 18.7 letters at six months, compared to 9.8 letters in patients with a longer disease duration (<a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>). Patients treated with aflibercept within two months improved by 20.2 letters (versus a ‐5.5 loss in the sham group) at six months, compared to 13.4 letters (versus ‐0.5 letters loss in the sham group) in patients with a longer disease duration (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>). A similar difference was seen at 12 months in those treated with aflibercept within two months of diagnosis who gained 19.5 letters (versus 2.1 letters in the sham group), compared to a gain of 13.7 letters (versus 5.5 letters in the sham group) seen in those with a longer disease duration (<a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>). </p> <p>Subgroup analysis according to baseline perfusion status was reported in two trials (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>). Eyes with ischaemic CRVO macular oedema at baseline gained +17.8 letters by six months when treated with aflibercept, compared to ‐2.3 letters in the sham group (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>). Eyes with non‐ischaemic CRVO macular oedema at baseline gained +17.1 letters by six months when treated with aflibercept, compared to ‐4.8 letters in the sham group (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>). Similarly, the <a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a> trial demonstrated that patients stratified by baseline perfusion status and treated with aflibercept for six months plus six months PRN had a similar gain from baseline in BCVA at 12 months, of +16.8 (SD 14.7 letters) and 17.4 (SD 16.1 letters) in the non‐ischaemic and ischaemic groups, respectively (<a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>). In contrast, eyes with no baseline retinal ischaemia in the sham group gained a mean 6.8 letters (SD 17.5) compared to a loss of 8.0 letters (SD 15.8 letters) in those with baseline ischaemia (<a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>). Importantly, this suggests a benefit of anti‐VEGF treatment with aflibercept in eyes with both ischaemic and non‐ischaemic CRVO macular oedema, and possibly a relatively greater gain in those with ischaemic CRVO macular oedema at baseline, whose visual outcome without treatment is worse. </p> <p>Subgroup analysis of patients according to baseline mean BCVA of better than or worse than 6/60 (20/200) was performed in two trials (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>). In patients with a baseline BCVA of 6/60 or worse, the mean change in Early Treatment of Diabetic Retinopathy Study (ETDRS) letter score was +21.9 versus 0 in the anti‐VEGF versus sham groups; in patients with a baseline BCVA of better than 6/60 the mean change was +15.9 versus ‐5.4 letters in the anti‐VEGF and sham groups, respectively (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>). In the second trial, at 12 months, patients with a baseline BCVA of 6/60 or worse also had a greater BCVA gain than those with a baseline BCVA of better than 6/60 (9.4 versus 2.4 letters for sham and 21.1 versus 16.0 letters for aflibercept monthly for six months then PRN for six months, respectively) (<a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>). This suggests a benefit of anti‐VEGF treatment compared to sham, especially for patients with a worse presenting baseline BCVA. </p> </section> <section id="CD007325-sec-0087"> <h5 class="title">Mean change in central retinal thickness (CRT) from baseline</h5> <p>All six studies measured this outcome but only two reported measures of dispersion (standard deviation or 95% CI) (<a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>; <a href="./references#CD007325-bbs2-0005" title="KingeB , StordahlPB , ForsaaV , FossenK , HaugstadM , HelgesenOH , et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham‐controlled ROCC Study. American Journal of Ophthalmology2010;150(3):310‐4. ">ROCC 2010</a>); unpublished data were supplied for a third study (<a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>, personal communication). The table below summarises and compares the data across the six RCTs. The mean change in CRT from baseline to six months ranged from a reduction of 102 µm to 169.3 µm in the sham groups, to a reduction of 243 µm to 457.2 µm in the treatment groups. Meta‐analysis of the data from three studies suggests that patients treated with anti‐VEGF agents have a mean reduction in CRT from baseline of 267.4 µm more than patients treated with sham, with 95% confidence that the true difference in the reduction lies between 211.4 µm and 323.4 µm. There was no significant statistical heterogeneity (I<sup>2</sup> = 8%) and also no significant difference between the different anti‐VEGF subgroups (I<sup>2</sup> = 0%) (see <a href="./references#CD007325-fig-0010" title="">Analysis 1.4</a>; <a href="#CD007325-fig-0006">Figure 6</a>). This represents a clinically significant benefit of anti‐VEGF treatment over sham treatment at six months. </p> <div class="figure" id="CD007325-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: Anti‐VEGF versus sham intravitreal injection, outcome: 1.4 Mean change from baseline in central retinal thickness at 6 months." data-id="CD007325-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_n/nCD007325-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: Anti‐VEGF versus sham intravitreal injection, outcome: 1.4 Mean change from baseline in central retinal thickness at 6 months. </p> </div> </div> </div> <p> <div class="table" id="CD007325-tblf-0006"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment group 1</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in CRT (µm)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment group 2</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in CRT (µm)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control group</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in CRT</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VEGF Trap‐Eye 2.0 mg (n = 114)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐457.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham injection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐144.8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ranibizumab 0.3 mg (n = 132)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐433.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ranibizumab 0.5 mg (n = 130)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐452.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham injection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐167</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg (n = 30)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐426</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham injection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐102</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VEGF Trap‐Eye 2.0 mg (n = 106)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐448.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham injection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐169.3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007325-bbs2-0005" title="KingeB , StordahlPB , ForsaaV , FossenK , HaugstadM , HelgesenOH , et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham‐controlled ROCC Study. American Journal of Ophthalmology2010;150(3):310‐4. ">ROCC 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ranibizumab 0.5 mg (n = 16)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐304</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham injection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐151</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pegaptanib sodium 0.3 mg (n = 33)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐243</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pegaptanib sodium 1.0 mg (n = 33)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐179</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham injection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐148</p> </td> </tr> </tbody> </table> </div> </p> <p>In all six trials, graphs of the mean change in CRT over time convincingly illustrated the rapid and beneficial effect of all the anti‐VEGF agents on resolution of macular oedema. The greatest reduction is seen within a month of the first injection in all trials, and the CRT reduction benefit is maintained throughout the treatment period. This is in marked contrast to the trajectory of change in CRT from baseline of the control patients, who demonstrate a more gentle, linear reduction in CRT over time. </p> <p>Three open‐label extension trials investigated the impact of immediate versus six‐month delayed treatment with anti‐VEGF on central retinal thickness (CRT) at 12 months. In these trials, patients initially randomised to sham injection for six months crossed over to receive treatment with anti‐VEGF agents from months 7 to 12, either every six weeks (<a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>), or monthly as required, and according to retreatment criteria (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>). In all three trials, the mean reduction in CRT was largely maintained from months 6 to 12 in the anti‐VEGF treatment groups (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>; <a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>). No significant difference in CRT, or the proportion of patients with residual macular oedema, was found between the anti‐VEGF and sham/anti‐VEGF groups at 12 months (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>; <a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>). These trials suggest that patients not receiving anti‐VEGF therapy for an initial six months catch up, in terms of improvement in CRT, following six months of anti‐VEGF therapy (<a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>; <a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>). It should be noted, however, that resolution towards normal CRT does not necessarily indicate restoration of normal structural integrity or neuroretinal function. </p> <p>One trial reported subgroup analysis for 12‐month outcomes by baseline retinal perfusion status (<a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>). Patients treated with six months of monthly aflibercept followed by six months of PRN aflibercept, versus sham, had a greater reduction from baseline in mean CRT, regardless of baseline non‐ischaemia or ischaemia (412.4 (SD 238.1) versus 201.2 (SD 226.4) for the non‐ischaemic treatment and sham groups, and 494.6 (SD 318.4) versus 294.3 (SD 258.6) for the ischaemic treatment and sham groups) (<a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>). </p> </section> </section> <section id="CD007325-sec-0088"> <h4 class="title">Complications and ocular adverse events</h4> <p>Certain complications may develop in the natural history of untreated CRVO macular oedema, in particular neovascularisation of the iris and retina, associated neovascular glaucoma and vitreous haemorrhage. Objective differentiation of complications versus adverse events associated with intravitreal injection is not always possible, and so we considered these outcomes together without a priori assumption in this review, at six months of follow‐up. In addition, one study reported safety data at 12 months (<a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>). Three studies included open‐label extension to 12 months (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>; <a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>). One study included open‐label extension to 24 months (<a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>). However, since patients initially randomised to sham injection received PRN anti‐VEGF therapy beyond six months in these three trials, there was no untreated control group for inclusion in meta‐analysis to compare outcomes at 12 months. Where the outcome developed with greater frequency in the sham group, we suggest that anti‐VEGF reduced progression to this complication. Where the outcome occurred with greater frequency in the anti‐VEGF group, we suggest it to be an adverse event associated with intravitreal injection or with anti‐VEGF therapy. The six trials did not all report all potential adverse events or complications at six months. Where data on a specific outcome are incomplete, we do not know whether no outcomes occurred, whether outcomes that occurred were not documented or reported, or whether there was selective reporting bias (<a href="./references#CD007325-fig-0011" title="">Analysis 1.5</a>). </p> <p>The development of iris or retinal neovascularisation was reported in all six studies. Across all studies, there were a total of 26/346 patients with this complication in the sham injection groups compared to 8/590 in the anti‐VEGF treatment groups at six months. The Peto odds ratio was 0.18 (95% CI 0.09 to 0.36), with no significant statistical heterogeneity (I<sup>2</sup> = 0%). This suggests that treatment with anti‐VEGF therapy reduced the odds of progression to this recognised complication of CRVO to about 18% of what it would have been without treatment. Four studies specifically reported that many of these patients received panretinal photocoagulation treatment for this (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>; <a href="./references#CD007325-bbs2-0005" title="KingeB , StordahlPB , ForsaaV , FossenK , HaugstadM , HelgesenOH , et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham‐controlled ROCC Study. American Journal of Ophthalmology2010;150(3):310‐4. ">ROCC 2010</a>; <a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a>). Cases of neovascular glaucoma at six months were reported in three trials (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>; <a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>) in a total of 1/479 patients treated with anti‐VEGF and 5/271 patients in the sham groups. The Peto odds ratio was 0.14 (95% CI 0.03 to 0.72), with no significant statistical heterogeneity (I<sup>2</sup> = 0%), suggesting a beneficial effect of anti‐VEGF therapy in reducing progression to about 14% of what it would have been without anti‐VEGF treatment. Additional non‐neovascular glaucoma cases were reported in two trials, in 0/170 patients in the anti‐VEGF groups and 1/100 patients in the control groups (<a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>; <a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a>). Considering longer durations of follow‐up, new iris neovascularisation developing between 6 and 12 months did not occur in the sham or treatment groups of the aflibercept or bevacizumab trials (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>; <a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>), but did develop in an additional two people in the sham/0.5 mg ranibizumab PRN group, and in an additional four persons in the 0.5 mg/0.5 mg PRN treatment groups of the <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a> trial. </p> <p>Vitreous haemorrhage was specifically reported in three studies (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>; <a href="./references#CD007325-bbs2-0005" title="KingeB , StordahlPB , ForsaaV , FossenK , HaugstadM , HelgesenOH , et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham‐controlled ROCC Study. American Journal of Ophthalmology2010;150(3):310‐4. ">ROCC 2010</a>), in a total of 14/390 patients treated with anti‐VEGF and 13/217 patients in the sham groups. The Peto odds ratio was 0.55 (95% CI 0.24 to 1.23) suggesting that treatment with anti‐VEGF reduced the odds of vitreous haemorrhage to about 55% of what it would have been without treatment. However, there was significant statistical heterogeneity (I<sup>2</sup> = 72%), perhaps reflecting that vitreous haemorrhage may result from intravitreal injection (i.e. an adverse event) or develop as a complication of CRVO and neovascularisation. Considering longer durations of follow‐up, vitreous haemorrhage developed in an additional one person in each of the treatment and sham/PRN treatment (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>) or sham (<a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>) groups in both the <a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a> and <a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a> trials between 6 and 12 months, and in two persons in the original 0.3 mg ranibizumab group, treated with PRN ranibizumab between months 6 and 12 (<a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>). </p> <p>All six studies specifically reported on endophthalmitis, with 1/590 cases occurring in the anti‐VEGF groups (following intravital infection of aflibercept) (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>) and 0/347 occurring in the sham groups (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>; <a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>; <a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>; <a href="./references#CD007325-bbs2-0005" title="KingeB , StordahlPB , ForsaaV , FossenK , HaugstadM , HelgesenOH , et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham‐controlled ROCC Study. American Journal of Ophthalmology2010;150(3):310‐4. ">ROCC 2010</a>; <a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a>). The Peto odds ratio was 5.20 (95% CI 0.09 to 287.41), reflecting that the odds of this outcome are best estimated at over five times higher in those treated with intravitreal injection or with anti‐VEGF therapy compared to no injection or anti‐VEGF treatment, although the CI reflects considerable uncertainty. This one case was culture‐positive for coagulase negative <i>Staphylococcus</i> and was considered to be associated with intravitreal injection. There were no additional cases of endophthalmitis at 12 months (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>; <a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>; <a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>). However, two cases of endophthalmitis were reported after 12 months in the HORIZON extension to the CRUISE trial, in patients in the 0.3 mg/0.5 mg group (<a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>). </p> <p>Five trials reported no retinal detachments at six months (<a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>; <a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>; <a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>; <a href="./references#CD007325-bbs2-0005" title="KingeB , StordahlPB , ForsaaV , FossenK , HaugstadM , HelgesenOH , et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham‐controlled ROCC Study. American Journal of Ophthalmology2010;150(3):310‐4. ">ROCC 2010</a>; <a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a>). One retinal detachment developed between months 6 and 12 in the group treated with PRN aflibercept (<a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>), but there were no additional detachments in three open‐label extension trials (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>; <a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>). </p> <p>Three studies reported retinal artery occlusion in 3/391 patients in the anti‐VEGF groups and 0/217 patients in the sham groups (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>; <a href="./references#CD007325-bbs2-0005" title="KingeB , StordahlPB , ForsaaV , FossenK , HaugstadM , HelgesenOH , et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham‐controlled ROCC Study. American Journal of Ophthalmology2010;150(3):310‐4. ">ROCC 2010</a>). The Peto odds ratio was 5.37 (95% CI 0.51 to 55.03), with no significant statistical heterogeneity (I<sup>2</sup> = 0%), reflecting that the odds of this outcome are over five times higher in those treated with intravitreal injection or with anti‐VEGF therapy compared to no injection or anti‐VEGF treatment. No additional events were reported between 6 and 12 months (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>). </p> <p>Cataract was reported in four out of 390 patients treated with anti‐VEGF at six months versus 0 out of 217 receiving sham (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>; <a href="./references#CD007325-bbs2-0005" title="KingeB , StordahlPB , ForsaaV , FossenK , HaugstadM , HelgesenOH , et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham‐controlled ROCC Study. American Journal of Ophthalmology2010;150(3):310‐4. ">ROCC 2010</a>). All patients developing cataract received ranibizumab. The Peto odds ratio was 4.51 (95% CI 0.56 to 36.48) reflecting that the odds of developing cataract may be more than four times higher in those treated with anti‐VEGF compared to sham. In the 12‐month open‐label extension trial, cataract was reported in a total of two patients treated with sham then PRN ranibizumab for six months, and an additional 10 patients in the treatment groups (<a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>). At 12 months one person in each group receiving PRN aflibercept between 6 and 12 months developed cataract (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>). </p> <p>There was variable reporting of other more minor adverse events and complications in the studies, including subconjunctival haemorrhage, eye pain, elevation in intraocular pressure and ocular inflammation. </p> </section> <section id="CD007325-sec-0089"> <h4 class="title">Non‐ocular adverse events potentially associated with anti‐VEGF therapy or intravitreal injection </h4> <p>Five trials reported two cases of myocardial infarction in 575 patients treated with anti‐VEGF and two cases out of 333 treated with sham (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>; <a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>; <a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>; <a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a>). The Peto odds ratio was 0.57 (95% CI 0.08 to 3.88), indicating that anti‐VEGF treatment may be associated with lower odds of myocardial infarction compared to sham (<a href="./references#CD007325-fig-0012" title="">Analysis 1.6</a>). Four trials reported one case of transient ischaemic attack (TIA) out of 575 patients, which occurred in the 0.5 mg treatment group of the <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a> trial, compared to no cases in 333 control patients (<a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>; <a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>; <a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>; <a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a>). The Peto odds ratio was 1.49 (95% CI 0.06 to 36.29) suggesting that anti‐VEGF treatment may be associated with higher odds of TIA, as compared to sham treatment. Hypertension was reported in 14 out of 479 patients receiving anti‐VEGF, compared to 4 out 271 receiving sham (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>; <a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>). The Peto odds ratio was 1.27 (95% CI 0.13 to 12.29) suggesting that anti‐VEGF treatment may be associated with higher odds of hypertension compared to sham. Upper respiratory tract infections were reported more frequently in association with aflibercept treatment, in 14 out of 218 as compared to 6 out of 142 with sham treatment (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>). The Peto odds ratio was 1.89 (95% CI 0.20 to 17.94) suggesting that aflibercept treatment may be associated with higher odds of nasopharyngitis than sham injection. No other significant systemic adverse events were reported in the six trials. </p> </section> <section id="CD007325-sec-0090"> <h4 class="title">The number of anti‐VEGF or sham injections administered</h4> <p>The number of anti‐VEGF or sham injections was prespecified in the protocol of all trials for a fixed period, which ranged from three months (<a href="./references#CD007325-bbs2-0005" title="KingeB , StordahlPB , ForsaaV , FossenK , HaugstadM , HelgesenOH , et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham‐controlled ROCC Study. American Journal of Ophthalmology2010;150(3):310‐4. ">ROCC 2010</a>) to six months (<a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>, <a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>, <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>, <a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>, <a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a>). Numerous trials included a pro re nata (PRN) treatment period ranging from a further three months (<a href="./references#CD007325-bbs2-0005" title="KingeB , StordahlPB , ForsaaV , FossenK , HaugstadM , HelgesenOH , et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham‐controlled ROCC Study. American Journal of Ophthalmology2010;150(3):310‐4. ">ROCC 2010</a>) to a further six months (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>) or more (<a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>), in which the anti‐VEGF agent was given to all groups according to protocol‐specified retreatment criteria. One trial included a PRN treatment period of a further six months in which randomisation to sham or anti‐VEGF agent was maintained (<a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>). The following table summarises the mean injections given in each of the trials. </p> <p> <div class="table" id="CD007325-tblf-0007"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean number of injections months 0 to 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean number of injections months 6 to 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Notes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (sham or ranibizumab)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.9 (SE 0.3) in sham + PRN ranibizumab; 2.7 (SE 0.2) in ranibizumab + PRN ranibizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRN ranibizumab 6 to 12 m</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (sham or 0.3 mg or 0.5 mg ranibizumab)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.8 in 0.3 mg group;</p> <p>3.3 in 0.5 mg group;</p> <p>3.7 in sham/0.5 mg group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRN ranibizumab 6 to 12m</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (sham or bevacizumab)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (bevacizumab for both groups)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fixed injection schedule</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (sham or aflibercept)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>From 0 to 52 weeks: 11.8 (SD 2.8) aflbercept; 10.5 (SD 4.2) sham</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRN ranibizumab or sham from 6 to 12 m</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007325-bbs2-0005" title="KingeB , StordahlPB , ForsaaV , FossenK , HaugstadM , HelgesenOH , et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham‐controlled ROCC Study. American Journal of Ophthalmology2010;150(3):310‐4. ">ROCC 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.3 (SD 0.9) ranibizumab; 5.5 (SD 1.1) sham</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRN ranibizumab or sham from 3 to 6 m</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (sham or pegaptanib sodium)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fixed injection schedule</p> </td> </tr> </tbody> </table> </div> </p> </section> <section id="CD007325-sec-0091"> <h4 class="title">The number and type of additional interventions administered</h4> <p>No additional interventions to treat CRVO‐MO were reported in any of the trials.</p> </section> <section id="CD007325-sec-0092"> <h4 class="title">Economic data</h4> <p>No trials included economic data. Aside from these six RCTs, the remainder of the literature identified through this review's electronic search was based on open‐label, prospective studies, retrospective chart reviews, case reports and case series with relatively short follow‐up periods. </p> </section> <section id="CD007325-sec-0093"> <h4 class="title">Quality of life</h4> <p>Three trials included the mean change in total score from baseline to six months on the National Eye Institute 25‐item Visual Function Questionnaire, NEI VFQ‐25 (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>; <a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>); however, only one study reported data sufficient for analysis (<a href="./references#CD007325-fig-0013" title="">Analysis 1.7</a>). Specifically, in the <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a> trial, patients in the 0.3 mg and 0.5 mg ranibizumab groups had a mean gain of 7.1 (95% CI 5.2 to 9.0) and 6.2 (95% 4.3 to 8.0) points, respectively, compared to 2.8 (95% CI 0.8 to 4.7) in the sham group (P &lt; 0.05 for each ranibizumab group versus sham), even though the study eye was the worse seeing eye in most cases. Similarly, in the <a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a> and <a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a> trials, patients in the 2.0 mg aflibercept groups gained an average of 7.2 points and 7.5 points, respectively, compared to 0.8 points and 3.5 points, in the sham groups. At 52 weeks, further slight gains were reported from baseline in the treatment (7.8 points) and sham (4.5 points) groups in the <a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a> trial. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007325-sec-0094" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007325-sec-0094"></div> <section id="CD007325-sec-0095"> <h3 class="title" id="CD007325-sec-0095">Summary of main results</h3> <p>All six trials demonstrated that repeated intravitreal anti‐vascular endothelial growth factor (anti‐VEGF) treatment was associated with (predominantly) significant improvements in the primary and secondary outcomes at six months compared to sham, and no significant safety concerns relating to the drug were identified in this time. Specifically, the proportion of treated patients gaining 15 letters or more of visual acuity ranged from 36.4% for 0.3 mg pegaptanib sodium (<a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a>), to 60.2% for 2.0 mg aflibercept (<a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>). The mean gain in visual acuity ranged from 7.1 letters in those treated with 0.3 mg pegaptanib sodium (<a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a>) to 18.0 letters in those treated with 2.0 mg aflibercept (<a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>). The proportion of treated patients losing 15 letters or more of visual acuity ranged from 1.5% (<a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>) to 13.3% (<a href="./references#CD007325-bbs2-0005" title="KingeB , StordahlPB , ForsaaV , FossenK , HaugstadM , HelgesenOH , et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham‐controlled ROCC Study. American Journal of Ophthalmology2010;150(3):310‐4. ">ROCC 2010</a>), in patients receiving 0.5 mg ranibizumab. Participants receiving anti‐VEGF treatment had a greater reduction in mean central retinal thickness (CRT) from baseline than patients receiving sham, indicating enhanced resolution of macular oedema. The reduction ranged from ‐179 to ‐243 μm in patients receiving pegaptanib sodium (<a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a>), to between ‐426 and ‐457 μm in participants receiving ranibizumab, bevacizumab and aflibercept (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>; <a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>; <a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>). Participants in the treatment groups of the <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>, <a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a> and <a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a> trials reported an improvement in quality of life, with a gain of approximately seven points on the National Eye Institute 25‐item Visual Function Questionnaire (NEI VFQ‐25) instrument at six months. The three open‐label extension trials demonstrated that in the anti‐VEGF treatment groups, the visual acuity and CRT gains seen at six months were maintained at 12 months, and no new safety concerns were identified in the treated groups (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>; <a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>). </p> <p>In contrast, the outcomes in the sham groups were significantly worse and were similar across the six trials. Specifically, a gain of 15 or more letters at six months was reported in between 12% (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>) and 28% (<a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a>), whilst a loss of 15 letters or more was reported in between 15% (<a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>) and 31% (<a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a>). In general, after six months of sham injection there was a negligible mean change from baseline visual acuity, ranging from ‐4 letters (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>) to +3.3 letters (<a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>). There was some reduction in mean central retinal thickness from baseline, ranging from 102 μm (<a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>) to 169 μm (<a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>). These outcomes are summarised in <a href="./full#CD007325-tbl-0001">summary of findings Table for the main comparison</a>. Participants in the sham groups reported minimal functional gain in quality of life from baseline to six months on the NEI VFQ‐25 instrument, with an average change of 0.8 points (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>), 2.8 points (<a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>) and 3.5 points (<a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>). </p> <p>Allowing for variability resulting from the relatively small sample sizes, the six randomised controlled trials (RCTs) included participants with broadly similar baseline characteristics in both the sham and treatment groups (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>; <a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>; <a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>; <a href="./references#CD007325-bbs2-0005" title="KingeB , StordahlPB , ForsaaV , FossenK , HaugstadM , HelgesenOH , et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham‐controlled ROCC Study. American Journal of Ophthalmology2010;150(3):310‐4. ">ROCC 2010</a>; <a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a>). The mean duration from diagnosis to first treatment ranged from 61 days (<a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>) to 80 days (<a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a>). The mean age ranged from 62 years (<a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>) to 72 years (<a href="./references#CD007325-bbs2-0005" title="KingeB , StordahlPB , ForsaaV , FossenK , HaugstadM , HelgesenOH , et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham‐controlled ROCC Study. American Journal of Ophthalmology2010;150(3):310‐4. ">ROCC 2010</a>). The proportion of male patients ranged from 53% (<a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a>) to 60% (<a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>). The mean baseline BCVA ranged from 52 letters (<a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>) to 43 letters (<a href="./references#CD007325-bbs2-0005" title="KingeB , StordahlPB , ForsaaV , FossenK , HaugstadM , HelgesenOH , et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham‐controlled ROCC Study. American Journal of Ophthalmology2010;150(3):310‐4. ">ROCC 2010</a>), and the percentage of patients with a baseline visual acuity worse than 35 letters (6/60) ranged from 17% (<a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>) to 32% (<a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>). The mean baseline central retinal thickness ranged from 619 µm (<a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a>) to 721 µm (<a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>). Two trials included only patients with non‐ischaemic central retinal vein occlusion (CRVO) macular oedema (<a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>; <a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a>), and four trials included a mixed cohort of ischaemic and non‐ischaemic patients. The proportion of patients with baseline ischaemic CRVO macular oedema was 8.2% (plus 8.2% undetermined) in the <a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a> trial of aflibercept; 11.7% in the bevacizumab trial (<a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>); 15.6% in the smaller ranibizumab trial (<a href="./references#CD007325-bbs2-0005" title="KingeB , StordahlPB , ForsaaV , FossenK , HaugstadM , HelgesenOH , et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham‐controlled ROCC Study. American Journal of Ophthalmology2010;150(3):310‐4. ">ROCC 2010</a>) and 15.5% (plus 16.6% undetermined) in the other trial of aflibercept (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>). </p> <p>Subgroup analyses to investigate the impact of treatment delay were performed in a few studies (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>; <a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>). This suggested that the greatest benefit of anti‐VEGF treatment occurs in patients with a shorter duration between diagnosis and treatment (analysis was based on before and after two months or 90 days). Three open‐label extension trials, in which patients randomised to sham injection for six months crossed over to receive PRN (as needed) anti‐VEGF between months 7 and 12, further corroborated this. Six‐month delayed anti‐VEGF therapy resulted in resolution of macular oedema, with no significant differences between groups at 12 months in mean CRT. However, whilst visual outcomes improved in groups treated with anti‐VEGF on a PRN basis after six months, the visual outcomes remained significantly worse at 12 months in these groups compared to the groups initially randomised to anti‐VEGF therapy (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>; <a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>). Only one open‐label extension trial, the HORIZON trial, considered longer‐term outcomes at 24 months (<a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>). It is difficult to determine whether the lack of sustained benefit of anti‐VEGF treatment at 24 months, with worsening of functional (but not anatomical) outcomes compared to 12 months, reflected reduced efficacy of anti‐VEGF over time, or whether it was related to the lower assessment and treatment frequency in months 12 to 24, or to the high probability of attrition bias in the outcome data resulting from early termination of the trial. </p> <p>Subgroup analyses to investigate the impact of retinal perfusion status on visual outcomes were performed in a few studies (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>). These demonstrated that without anti‐VEGF treatment, eyes with baseline ischaemic CRVO macular oedema have a worse visual prognosis than eyes with non‐ischaemic CRVO macular oedema, but that both groups experience similar gains in visual acuity and anatomical resolution of macular oedema with anti‐VEGF therapy. Subgroup analyses with stratification by baseline visual acuity (better or worse than 6/60) indicated that greater absolute gains in visual acuity are seen in patients with a baseline BCVA worse than 6/60 than with a baseline acuity better than 6/60, in both sham and treatment groups (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>). </p> <p>Anti‐VEGF therapy was associated with significant reduction in the odds of developing iris or retinal neovascularisation or neovascular glaucoma at six months compared to sham treatment (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>; <a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>; <a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>; <a href="./references#CD007325-bbs2-0005" title="KingeB , StordahlPB , ForsaaV , FossenK , HaugstadM , HelgesenOH , et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham‐controlled ROCC Study. American Journal of Ophthalmology2010;150(3):310‐4. ">ROCC 2010</a>; <a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a>). Recognised complications of intravitreal injection therapy, including endophthalmitis, rhegmatogenous retinal detachment and retinal artery occlusion, were reported at very low frequency in some of the treatment groups. No significant association between anti‐VEGF therapy and serious systemic adverse events was identified at six months. </p> <p>In summary, despite some variability in baseline characteristics between the trials, all four anti‐VEGF agents were demonstrated to enhance the anatomical resolution of macular oedema, to stabilise the visual acuity in some participants and to significantly improve the visual acuity in approximately half of those treated, with associated gains in quality of life in the trials which included this outcome, with no significant safety concerns up to 12 months. The 12‐month <a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a> trial and the three open‐label extension trials demonstrated a benefit to sham patients commenced on anti‐VEGF treatment following a delay of six months (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>; <a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>). Subgroup analyses indicated benefit of anti‐VEGF treatment to both ischaemic and non‐ischaemic CRVO macular oedema patients. The results of this systematic review and meta‐analysis demonstrate that treatment with anti‐VEGF agents confers significant clinical gains in all outcomes of interest compared to no treatment. </p> </section> <section id="CD007325-sec-0096"> <h3 class="title" id="CD007325-sec-0096">Overall completeness and applicability of evidence</h3> <p>One limitation of some of the trials was their relatively small sample sizes; these ranged from 14 participants per group (<a href="./references#CD007325-bbs2-0005" title="KingeB , StordahlPB , ForsaaV , FossenK , HaugstadM , HelgesenOH , et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham‐controlled ROCC Study. American Journal of Ophthalmology2010;150(3):310‐4. ">ROCC 2010</a>) to 132 participants per group (<a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>). Whilst this may have reduced the power to identify a significant difference between the treatment and sham groups in the main and secondary outcomes of interest (<a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a>), the treatment effect associated with anti‐VEGF therapy in most studies was sufficiently large to yield significant differences from the control groups (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>; <a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>; <a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>; <a href="./references#CD007325-bbs2-0005" title="KingeB , StordahlPB , ForsaaV , FossenK , HaugstadM , HelgesenOH , et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham‐controlled ROCC Study. American Journal of Ophthalmology2010;150(3):310‐4. ">ROCC 2010</a>). Two different treatment doses were investigated in comparison to sham in the <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a> and <a href="./references#CD007325-bbs2-0006" title="CiullaTA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (Macugen): a one‐year study. American Academy of Ophthalmology 2007. Conference abstract 199. CsakyKG . Pegaptanib (Macugen) for macular edema in central retinal vein occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007. Conference abstract 269. PatelSS . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): anatomical outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 311. WellsJA . Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion. Investigative Ophthalmology and Visual Science2006; Vol. 47:ARVO E‐abstract 4279. WellsJA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology 2006. Conference abstract 288. WellsJA , WroblewskiJJ . Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐abstract 1544. WroblewskiJJ , WellsJA3rd , AdamisAP , BuggageRR , CunninghamETJr , GoldbaumM , et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology2009;127(4):374‐80. ">Wroblewski 2009</a> trials, but neither trial had sufficient power to investigate outcome differences between these doses. </p> <p>A second limitation in five out of six of the trials was the relatively short follow‐up period of approximately six months, which did not permit assessment of how long the apparent benefits of treatment with anti‐VEGF are sustained. One trial reported 12‐month outcomes compared to sham (<a href="./references#CD007325-bbs2-0004" title="HolzFG , RoiderJ , OguraY , KorobelnikJF , SimaderC , GroetzbachG , et al. VEGF Trap‐Eye for macular oedema secondary to central retinal vein occlusion: 6‐month results of the phase III GALILEO study. British Journal of Ophthalmology2013;97(3):278‐84. KorobelnikJF , HolzFG , RoiderJ , OguraY , SimaderC , Schmidt‐ErfurthU , for the GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one‐year results of the Phase 3 GALILEO Study. Ophthalmology2014;121(1):202‐8. ">GALILEO 2013</a>), and three open‐label extension trials yielded safety data to 12 months (<a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a>; <a href="./references#CD007325-bbs2-0003" title="EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve‐month results from a prospective, randomized study. Ophthalmology2012;119(12):2587‐91. EpsteinDL , AlgverePV , vonWendtG , SeregardS , KvantaA . Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double‐masked clinical study. Ophthalmology2012;119(6):1184‐9. ">Epstein 2012</a>) and 24 months (<a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a>), for the treatment and cross‐over groups. Ocular or systemic adverse events occurring at a longer latency from treatment may have been missed. </p> <p>Whilst the treatment of CRVO macular oedema with these four anti‐VEGF agents appears very promising, the applicability of the available trial data to important subgroups of patients in clinical practice is not known. For example, since patients who had persisting CRVO macular oedema for more than one year were excluded from recruitment into the trials, the efficacy and safety of anti‐VEGF therapy in these patients is not known. Patients with previous retinal vein occlusion, or other co‐morbid eye disease including diabetic retinopathy and age‐related macular degeneration, were also excluded, even though age and diabetes are among the established risk factors for CRVO (<a href="./references#CD007325-bbs2-0078" title="ShahsuvaryanML , MelkonyanAK . Central retinal vein occlusion risk profile: a case‐control study. European Journal of Ophthalmology2003;13(5):445‐52. ">Shahsuvaryan 2003</a>). It is not uncommon for patients in clinical practice to have multiple ocular and systemic pathologies. Furthermore, the CVOS Study reported that 29% of patients with CRVO present with a visual acuity of 6/12 or better (<a href="./references#CD007325-bbs2-0028" title="CVOS Group. Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group. Archives of Ophthalmology1997;115(10):1275. ">CVOS Group 1997</a>), but as these participants were mostly excluded it is not possible to determine whether treatment with anti‐VEGF might confer sufficient benefit in this group to outweigh the risks associated with intravitreal injection. </p> </section> <section id="CD007325-sec-0097"> <h3 class="title" id="CD007325-sec-0097">Quality of the evidence</h3> <p>The six included RCTs were small to moderate in size but were well designed with a low risk of bias in the majority of domains. They can therefore be considered to provide reasonably high‐quality evidence on 6‐ to 12‐month outcomes for the specific cohort of participants studied. </p> <p>Data from numerous non‐randomised studies were reviewed in the previous publication of this review (<a href="./references#CD007325-bbs2-0091" title="BraithwaiteT , NanjiAA , GreenbergPB . Anti‐vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion. Cochrane Database of Systematic Reviews2010, Issue 10. [DOI: 10.1002/14651858.CD007325] ">Braithwaite 2010</a>). A comprehensive search for such data was not performed, and these tables were not included or updated in the current review. </p> </section> <section id="CD007325-sec-0098"> <h3 class="title" id="CD007325-sec-0098">Agreements and disagreements with other studies or reviews</h3> <p>We are not aware of any other systematic reviews on the use of anti‐VEGF agents for the treatment of CRVO macular oedema. However, these agents have been administered intravitreally in numerous other ophthalmological contexts, and a good short‐term safety profile is emerging, with a low incidence of serious ocular and systemic adverse events. A systematic review including 278 studies on 9061 participants who received 49,584 intravitreal anti‐VEGF injections, specifically, ranibizumab (19,908 injections given over a mean of 16 months), bevacizumab (11,018 injections given over a mean of five months) and pegaptanib sodium (18,658 injections given over a mean of 11 months) reported a low incidence of all serious ocular adverse events with all three agents (<a href="./references#CD007325-bbs2-0083" title="van derReisMI , LaHeijEC , DeJong‐HesseY , RingensPJ , HendrikseF , SchoutenJS . A systematic review of the adverse events of intravitreal anti‐vascular endothelial growth factor injections. Retina (Philadelphia, Pa.)2011;31(8):1449‐69. ">van der Reis 2011</a>). Specifically, there was a low cumulative incidence (per 100 injections) of endophthalmitis (0.04% to 0.11%), retinal detachment (0.01% to 0.08%), intraocular inflammation (0.25% to 1.06%), elevated intraocular pressure (IOP) (0.15% to 3.60%), intraocular haemorrhage (0.03% to 0.18%) and cataract progression (0.05% to 0.64%) (<a href="./references#CD007325-bbs2-0083" title="van derReisMI , LaHeijEC , DeJong‐HesseY , RingensPJ , HendrikseF , SchoutenJS . A systematic review of the adverse events of intravitreal anti‐vascular endothelial growth factor injections. Retina (Philadelphia, Pa.)2011;31(8):1449‐69. ">van der Reis 2011</a>). Similarly, five cases of retinal detachment were reported over three years out of 35,942 anti‐VEGF intravitreal injections performed at six high‐volume centres in Germany (<a href="./references#CD007325-bbs2-0063" title="MeyerCH , MichelsS , RodriguesEB , HagerA , MennelS , SchmidtJC , et al. Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injections. Acta Ophthalmologica2011;89(1):70‐5. ">Meyer 2011</a>). All retinal detachments occurred within two to six days of injection, and were more frequent in myopic patients (<a href="./references#CD007325-bbs2-0063" title="MeyerCH , MichelsS , RodriguesEB , HagerA , MennelS , SchmidtJC , et al. Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injections. Acta Ophthalmologica2011;89(1):70‐5. ">Meyer 2011</a>). Other less serious side effects associated with intravitreal injections have included lid irritation, ocular discomfort and foreign body sensation, transient vision blurring, subconjunctival haemorrhage, mild anterior chamber inflammation and mild vitreitis, uveitis and raised IOP (<a href="./references#CD007325-bbs2-0060" title="LynchSS , ChengCM . Bevacizumab for neovascular ocular diseases. Annals of Pharmacotherapy2007;41(4):614‐25. ">Lynch 2007</a>). Systemic adverse events including stroke, myocardial infarction and blood pressure elevation have been reported following intravenous administration of bevacizumab at doses more than 300 times higher than are used for ophthalmic indications (<a href="./references#CD007325-bbs2-0060" title="LynchSS , ChengCM . Bevacizumab for neovascular ocular diseases. Annals of Pharmacotherapy2007;41(4):614‐25. ">Lynch 2007</a>). Wu et al reported systemic adverse events at one year in 1.5% of patients following intravitreal administration of 4303 bevacizumab injections into 1310 eyes. These adverse events included acute systolic blood pressure elevation (0.59%), cerebrovascular accident (0.5%), myocardial infarction (0.4%), iliac artery aneurysm (0.17%), toe amputation (0.17%) and death (0.4%) (<a href="./references#CD007325-bbs2-0088" title="WuL , Martinez‐CastellanosMA , Quiroz‐MercadoH , ArevaloJF , BerrocalMH , FarahME , et al. Twelve‐month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan‐American Collaborative Retina Study Group (PACORES). Graefes Archive for Clinical and Experimental Ophthalmology2008;246(1):81‐7. ">Wu 2008</a>). In the systematic review of three anti‐VEGF agents, systemic adverse events were similarly infrequent, with a low cumulative incidence (per 100 injections) of heart disease (0.05% to 0.34%), vascular disease (0.01% to 0.05%), hypertension (0.15% to 0.55%), cerebrovascular accident (CVA) or transient ischaemic attack (TIA) (0.01% to 0.07%) and thromboembolic events (0.07% to 0.19%) (<a href="./references#CD007325-bbs2-0083" title="van derReisMI , LaHeijEC , DeJong‐HesseY , RingensPJ , HendrikseF , SchoutenJS . A systematic review of the adverse events of intravitreal anti‐vascular endothelial growth factor injections. Retina (Philadelphia, Pa.)2011;31(8):1449‐69. ">van der Reis 2011</a>). The available evidence for the short‐term safety profile of these agents is reassuring, but the follow‐up periods are still too short, and the total number of treated patients too small to detect serious adverse events that occur at very low incidence, or at long latency from the treatment period. </p> <p>It will be important to determine the relative effectiveness and safety of anti‐VEGF agents versus other interventions for the treatment of CRVO macular oedema, but no head‐to‐head trial data are available yet. Comparison with RCT data on intravitreal corticosteroids will be particularly important, as both anti‐VEGF agents and steroid implants have now been approved for the treatment of CRVO macular oedema in various countries, and are being used extensively off‐label in others. Differences in baseline characteristics of participants recruited to the existing trials, comparing either anti‐VEGF agents or steroid treatments to sham, render outcome comparison challenging at present. For example, the average duration of disease was less than two months in 62% patients recruited to the <a href="./references#CD007325-bbs2-0001" title="BoyerD , HeierJ , BrownDM , ClarkWL , BerlinerAJ , GroetzbachG , et al. Vascular endothelial growth factor Trap‐Eye for macular edema secondary to central retinal vein occlusion: six‐month results of the phase 3 COPERNICUS study. Ophthalmology2012;119(5):1024‐32. BrownDM , HeierJS , ClarkWL , BoyerDS , VittiR , BerlinerAJ , et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‐year results from the phase 3 COPERNICUS study. American Journal of Ophthalmology2013;155(3):429‐37. ">Copernicus 2012</a> trial, and less than three months in 69% participants in the <a href="./references#CD007325-bbs2-0002" title="BhisitkulRB , CampochiaroPA , ShapiroH , RubioRG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology2013;120(5):1057‐63. BrownDM , CampochiaroPA , SinghRP , LiZ , GrayS , SarojN , et al. Ranibizumab for macular edema following central retinal vein occlusion: six‐month primary end point results of a phase III study. Ophthalmology2010;117(6):1124‐33. CampochiaroPA , BhisitkulRB , ShapiroH , RubioRG . Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology2013;120(4):795‐802. CampochiaroPA , BrownDM , AwhCC , LeeSY , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve‐month outcomes of a phase III study. Ophthalmology2011;118:2041‐9. HeierJS , CampochiaroPA , YauL , LiZ , SarojN , RubioRG , LaiP . Ranibizumab for macular edema due to retinal vein occlusions: long‐term follow‐up in the HORIZON trial. Ophthalmology2012;119:802‐9. SunerIJ , BresslerNM , VarmaR , LeeP , DolanCM , WardJ , et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmology2013;131(7):851‐6. VarmaR , BresslerNM , SunerI , LeeP , DolanCM , WardJ , for the BRAVO and CRUISE Study Groups. Improved vision‐related function after ranibizumab for macular edema after retinal vein occlusion. Ophthalmology2012;119(10):2108‐18. ">CRUISE 2010</a> trial, but in only 39% participants recruited to the <a href="./references#CD007325-bbs2-0077" title="IpMS , ScottIU , VanVeldhuisenPC , OdenNL , BlodiBA , FisherM , et al. SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: The standard care vs corticosteroid for retinal vein occlusion (SCORE) study report 5. Archives of Ophthalmology2009;127(9):1101‐14. ">SCORE 2009</a> trial and 17% recruited to the <a href="./references#CD007325-bbs2-0066" title="HallerJA , BandelloF , BelfortR , BlumenkranzMS , GilliesM , HeierJ , et al. The OZURDEX GENEVA Study Group. Randomized, sham‐controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology2010;117(6):1134‐46. ">Ozurdex GENEVA 2010</a> trial. Numerous head‐to‐head RCTs comparing different anti‐VEGF agents and steroid treatments are currently underway and will begin to address this. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007325-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/urn:x-wiley:14651858:media:CD007325:CD007325-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_t/tCD007325-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Results from searching for studies for inclusion in the review (as of 29 October 2013)." data-id="CD007325-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_n/nCD007325-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Results from searching for studies for inclusion in the review (as of 29 October 2013).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/full#CD007325-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_n/nCD007325-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007325-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/urn:x-wiley:14651858:media:CD007325:CD007325-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_t/tCD007325-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD007325-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_n/nCD007325-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/full#CD007325-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_n/nCD007325-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007325-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/urn:x-wiley:14651858:media:CD007325:CD007325-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_t/tCD007325-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007325-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_n/nCD007325-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/full#CD007325-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_n/nCD007325-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007325-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/urn:x-wiley:14651858:media:CD007325:CD007325-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_t/tCD007325-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: Anti‐VEGF versus sham intravitreal injection, outcome: 1.1 Gain of 15 letters or more at 6 months." data-id="CD007325-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_n/nCD007325-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: Anti‐VEGF versus sham intravitreal injection, outcome: 1.1 Gain of 15 letters or more at 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/full#CD007325-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_n/nCD007325-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007325-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/urn:x-wiley:14651858:media:CD007325:CD007325-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_t/tCD007325-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: Anti‐VEGF versus sham intravitreal injection, outcome: 1.2 Loss of 15 letters or more at 6 months." data-id="CD007325-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_n/nCD007325-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: Anti‐VEGF versus sham intravitreal injection, outcome: 1.2 Loss of 15 letters or more at 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/full#CD007325-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_n/nCD007325-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007325-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/urn:x-wiley:14651858:media:CD007325:CD007325-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_t/tCD007325-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: Anti‐VEGF versus sham intravitreal injection, outcome: 1.4 Mean change from baseline in central retinal thickness at 6 months." data-id="CD007325-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_n/nCD007325-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: Anti‐VEGF versus sham intravitreal injection, outcome: 1.4 Mean change from baseline in central retinal thickness at 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/full#CD007325-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_n/nCD007325-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007325-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/urn:x-wiley:14651858:media:CD007325:CD007325-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_t/tCD007325-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐VEGF versus sham intravitreal injection, Outcome 1 Gain of 15 letters or more at 6 months." data-id="CD007325-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_n/nCD007325-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF versus sham intravitreal injection, Outcome 1 Gain of 15 letters or more at 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/references#CD007325-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_n/nCD007325-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007325-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/urn:x-wiley:14651858:media:CD007325:CD007325-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_t/tCD007325-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐VEGF versus sham intravitreal injection, Outcome 2 Loss of 15 letters or more at 6 months." data-id="CD007325-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_n/nCD007325-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF versus sham intravitreal injection, Outcome 2 Loss of 15 letters or more at 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/references#CD007325-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_n/nCD007325-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007325-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/urn:x-wiley:14651858:media:CD007325:CD007325-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_t/tCD007325-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐VEGF versus sham intravitreal injection, Outcome 3 Mean change in BCVA from baseline at 6 months." data-id="CD007325-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_n/nCD007325-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF versus sham intravitreal injection, Outcome 3 Mean change in BCVA from baseline at 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/references#CD007325-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_n/nCD007325-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007325-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/urn:x-wiley:14651858:media:CD007325:CD007325-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_t/tCD007325-CMP-001-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐VEGF versus sham intravitreal injection, Outcome 4 Mean change from baseline in central retinal thickness at 6 months." data-id="CD007325-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_n/nCD007325-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF versus sham intravitreal injection, Outcome 4 Mean change from baseline in central retinal thickness at 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/references#CD007325-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_n/nCD007325-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007325-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/urn:x-wiley:14651858:media:CD007325:CD007325-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_t/tCD007325-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐VEGF versus sham intravitreal injection, Outcome 5 Adverse events and complications at 6 months (ocular)." data-id="CD007325-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_n/nCD007325-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF versus sham intravitreal injection, Outcome 5 Adverse events and complications at 6 months (ocular). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/references#CD007325-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_n/nCD007325-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007325-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/urn:x-wiley:14651858:media:CD007325:CD007325-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_t/tCD007325-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐VEGF versus sham intravitreal injection, Outcome 6 Adverse events (systemic) at 6 months." data-id="CD007325-fig-0012" src="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_n/nCD007325-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF versus sham intravitreal injection, Outcome 6 Adverse events (systemic) at 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/references#CD007325-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_n/nCD007325-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007325-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/urn:x-wiley:14651858:media:CD007325:CD007325-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_t/tCD007325-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐VEGF versus sham intravitreal injection, Outcome 7 Mean change in NEI VFQ 25 score (a vision‐related quality of life instrument)." data-id="CD007325-fig-0013" src="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_n/nCD007325-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF versus sham intravitreal injection, Outcome 7 Mean change in NEI VFQ 25 score (a vision‐related quality of life instrument). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/references#CD007325-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/media/CDSR/CD007325/image_n/nCD007325-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007325-tbl-0001"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Anti‐VEGF compared with sham injection for CRVO macular oedema</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with CRVO macular oedema of duration less than 9 months (mean &lt; 3 months) and no prior treatment </p> <p><b>Settings:</b> presenting baseline visual acuity ranging from 6 (&lt; 6/120) letters to 73 letters (˜6/12), both non‐ischaemic and ischaemic eyes (% ischaemic at baseline of included trials ranged from 0% to 16%) </p> <p><b>Intervention:</b> intravitreal injection with ranibizumab, bevacizumab, aflibercept or pegaptanib sodium </p> <p><b>Comparison:</b> sham injection </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Sham injection</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Anti‐VEGF injection</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BCVA gain of 15 letters or more</p> <p>(follow‐up: 6 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>182 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>493 per 1000</b> <br/> (382 to 635) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.71</b> (2.10 to 3.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>937<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Includes all 4 anti‐VEGF agents</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BCVA loss of 15 letters or more</p> <p>(follow‐up: 6 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>219 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 1000</b> <br/> (26 to 74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.20</b> (0.12 to 0.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>766<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Includes all 4 anti‐VEGF agents</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change in BCVA from baseline</p> <p>(follow‐up: 6 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change across control groups ranged from loss of 4 letters to gain of 3 letters</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean gain across treatment groups ranged from +7.1 letters to + 18.0 letters</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 15.23 letters</b> (11.57 to 18.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>937<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard deviation or 95% CI not reported in 2 studies (aflibercept and pegaptanib sodium) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change from baseline in central retinal thickness</p> <p>(follow‐up: 6 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction from baseline in CRT across control groups ranged from<br/> ‐102 to ‐169 microns (6 studies, 937 participants) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction from baseline in CRT in the intervention groups was ‐267 microns greater (‐211 to ‐323 microns) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD ‐267.4 µm</b> (211.4 to 323.4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>481<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard deviation or 95% CI not reported in 3 studies (aflibercept and pegaptanib sodium) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Complication: iris or retinal neovascularisation</p> <p>(follow‐up: 6 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>75 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000</p> <p>(7 to 27)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.18</b> (0.09 to 0.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>936</p> <p>(6 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Includes all 4 anti‐VEGF agents</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ocular adverse events: endophthalmitis at 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No cases in 347 participants treated with sham injection</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 case in 590 participants treated with intravitreal injection of anti‐VEGF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>937</p> <p>(6 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Includes all 4 anti‐VEGF agents</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change from baseline in quality of life score (NEI VFQ‐25 instrument)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean gain in quality of life score from baseline across control groups ranged from +0.8 to +3.5 points </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean gain in quality of life score from baseline across control groups ranged from +6.2 to +7.5 points </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>743</p> <p>(3 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard deviation or 95% CI not reported in 2 studies (aflibercept)<br/> &gt; 4‐point increase is considered a clinically relevant improvement </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Anti‐VEGF:</b> anti‐vascular endothelial growth factor; <b>BCVA:</b> best‐corrected visual acuity; <b>CI:</b> confidence interval;<b>CRT:</b> central retinal thickness; <b>CRVO:</b> central retinal vein occlusion; <b>MD:</b> mean difference; <b>NEI‐VFQ 25:</b> National Eye Institute Visual Functioning Questionnaire 25 question instrument; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>*Assumed risk was taken from the mean baseline risk from studies in the meta‐analysis and was equal to the total number of events in the control groups divided by the total number of participants in the control groups. </p> <p>Judgement of high quality: most evidence comes from RCTs at low risk of bias, with no unexplained heterogeneity and consistent results, low probability of publication bias, a large magnitude of effect or an apparent dose‐response gradient. </p> <p>Judgement of moderate quality: most of the evidence comes from RCTs with some limitations. For example, limitations include an unclear risk of bias in one or several domains or few participants and wide confidence intervals suggesting imprecision of evidence. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/full#CD007325-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007325-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Anti‐VEGF versus sham intravitreal injection</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Gain of 15 letters or more at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>937</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.71 [2.10, 3.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Pegaptanib sodium 0.3 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.56, 3.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Pegaptanib sodium 1.0 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.54, 2.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Ranibizumab 0.3 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.73 [1.55, 4.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Ranibizumab 0.5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.94 [1.74, 4.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Bevacizumab 1.25 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [1.38, 6.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Aflibercept 2.0 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.37 [2.04, 5.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Loss of 15 letters or more at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>766</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.12, 0.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Pegaptanib sodium 0.3 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.08, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Pegaptanib sodium 1.0 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.04, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Ranibizumab 0.3 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.09, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Ranibizumab 0.5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.05, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Bevacizumab 1.25 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.06, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Aflibercept 2.0 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.02, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mean change in BCVA from baseline at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>937</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.23 [11.57, 18.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Pegaptanib sodium 0.3 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Pegaptanib sodium 1.0 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Ranibizumab 0.3 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.90 [8.80, 15.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Ranibizumab 0.5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>14.06 [11.39, 16.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Bevacizumab 1.25 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>16.1 [5.63, 26.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 Aflibercept 2.0 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>21.3 [16.55, 26.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mean change from baseline in central retinal thickness at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>935</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐267.39 [‐323.36, ‐211.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Pegaptanib sodium 0.3 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Pegaptanib sodium 1.0 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Ranibizumab 0.3 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐266.7 [‐358.12, ‐175.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Ranibizumab 0.5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐232.26 [‐359.34, ‐105.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Bevacizumab 1.25 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐324.0 [‐452.64, ‐195.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Aflibercept 2.0 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse events and complications at 6 months (ocular) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Neovascularisation (iris or retina)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>936</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.09, 0.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Neovascular glaucoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>750</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.03, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Glaucoma (excluding neovascular)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.00, 4.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Vitreous haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>607</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.24, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 Endophthalmitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>937</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.20 [0.09, 287.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6 Retinal artery occlusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>608</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.37 [0.52, 55.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7 Retinal tear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>839</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.04, 3.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8 Retinal detachment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>747</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.9 Ocular inflammation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.16, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.10 Cataract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>607</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.51 [0.56, 36.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.11 Subconjunctival haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.55, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.12 Elevation in intraocular pressure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [0.54, 5.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.13 Eye pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.44 [0.83, 7.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse events (systemic) at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>908</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.08, 3.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 CVA or TIA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>908</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [0.06, 36.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>750</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.13, 12.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Nasopharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.89 [0.20, 17.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Mean change in NEI VFQ 25 score (a vision‐related quality of life instrument) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>743</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.84 [1.49, 6.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Ranibizumab 0.3 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.3 [0.94, 7.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Ranibizumab 0.5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.4 [0.09, 6.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Aflibercept 2.0 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Anti‐VEGF versus sham intravitreal injection</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007325.pub3/references#CD007325-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007325.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD007325-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007325-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD007325-note-0002">Français</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD007325-note-0001">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007325\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007325\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007325\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007325\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007325\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007325\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007325\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007325\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007325\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007325\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007325\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007325\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007325\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007325\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007325\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007325\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007325\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007325\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jiwTpTuf&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007325.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007325.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007325.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007325.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007325.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725384545"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007325.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725384548"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007325.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e79f0096a936e',t:'MTc0MDcyNTM4NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 